Bronchiectasis and Aspergillosis: Understanding the Connection

Bronchiectasis and aspergillosis are separate conditions, but they can sometimes occur together. Bronchiectasis damages and widens the airways, making it more difficult to clear mucus and inhaled particles such as Aspergillus spores.
Most people with bronchiectasis will not develop aspergillosis. However, Aspergillus-related disease may be overlooked because its symptoms can resemble bronchiectasis itself, a bacterial chest infection or a flare-up.
What is bronchiectasis?
Bronchiectasis is a long-term lung condition in which one or more airways become permanently widened, thickened or scarred.
Healthy airways use a thin layer of mucus and tiny hair-like structures called cilia to remove dust, microbes and other particles. In bronchiectasis, damaged airways often clear mucus less effectively. Mucus can collect in widened parts of the airway, allowing bacteria and fungi to remain in the lungs for longer.
Bronchiectasis may develop after:
- severe or repeated chest infections
- tuberculosis or other lung infections
- immune-system problems
- asthma or allergic bronchopulmonary aspergillosis
- cystic fibrosis or primary ciliary dyskinesia
- autoimmune or inflammatory conditions
- airway blockage or inhaled foreign material
Sometimes no clear cause is found.
Common symptoms include:
- a long-term cough
- regular production of sputum
- repeated chest infections
- breathlessness
- wheezing
- fatigue
- coughing up blood
Find out more about mucus clearance and airway-clearance techniques.
Why can bronchiectasis increase the risk of aspergillosis?
Bronchiectasis changes the structure of the airways and makes it harder to remove mucus. This may allow Aspergillus spores to remain in the airways and interact with the immune system.
The risk of Aspergillus-related disease may be influenced by:
- the extent and location of bronchiectasis
- how much mucus is retained
- the number and severity of chest infections
- underlying asthma or allergy
- previous tuberculosis or other structural lung disease
- corticosteroid or other immunosuppressive treatment
- the individual immune response to Aspergillus
Aspergillus may be present in sputum without causing active disease. This is sometimes described as colonisation or airway carriage. Other people develop an exaggerated allergic response, Aspergillus bronchitis or a chronic fungal infection.
Different Aspergillus-related conditions
Several different Aspergillus-related conditions can occur in people with bronchiectasis. They should not be treated as if they are all the same.
Aspergillus sensitisation
Aspergillus sensitisation means that the immune system has developed an allergic response to Aspergillus. It may be associated with wheezing, airway inflammation or more frequent exacerbations, but it is not the same as an active fungal infection.
Allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) occurs when the immune system reacts strongly to Aspergillus in the airways. It is traditionally associated with asthma and cystic fibrosis, but it can also occur in people with bronchiectasis who do not have either condition.
ABPA may cause:
- worsening wheeze or breathlessness
- thick or difficult-to-clear mucus
- recurrent chest symptoms
- increased eosinophils or IgE
- fleeting or changing shadows on chest imaging
- central bronchiectasis or high-attenuation mucus on CT
Read more about allergic bronchopulmonary aspergillosis.
Aspergillus bronchitis
Aspergillus bronchitis is a condition in which Aspergillus is repeatedly detected in the airways and is associated with a persistent productive cough, sputum and airway inflammation.
It is more likely to be considered when a person has:
- a chronic productive cough
- repeated detection of Aspergillus in sputum or bronchoscopy samples
- an increased Aspergillus IgG level
- no clear evidence of ABPA or CPA
Learn more in our guide to Aspergillus bronchitis.
Chronic pulmonary aspergillosis
Chronic pulmonary aspergillosis (CPA) is a long-term fungal infection that usually develops in structurally abnormal lungs. It may cause cavities, nodules, thickening around cavities or progressive changes over time.
Symptoms may include:
- persistent cough
- increasing breathlessness
- weight loss
- fatigue
- night sweats or a low-grade fever
- persistent sputum
- coughing up blood
Read more about the different types of CPA.
What does recent research show?
A 2025 review examined ABPA and other Aspergillus-related airway diseases in bronchiectasis. It concluded that ABPA, Aspergillus sensitisation, chronic Aspergillus infection and Aspergillus bronchitis may form a spectrum of disease influenced by both airway damage and the immune response.
The review estimated that ABPA affects approximately 4% of people with bronchiectasis, although estimates vary substantially between studies and populations. It also reported that Aspergillus sensitisation and chronic Aspergillus infection may collectively affect up to 30% of people with bronchiectasis.
These figures should be interpreted cautiously. They do not mean that one in three people with bronchiectasis has an active fungal infection. Sensitisation, colonisation and active disease are different findings, and not everyone with a positive test requires antifungal treatment.
The review argued that Aspergillus-related disease may be associated with more severe bronchiectasis and more frequent exacerbations. It also noted that ABPA may sometimes contribute to bronchiectasis, rather than simply occurring as a result of already damaged airways.
A separate 2026 international study found that sensitisation to particular Aspergillus allergens was associated with markers of higher-risk bronchiectasis, including exacerbations, hospital admissions and Pseudomonas aeruginosa infection. The study does not prove that sensitisation causes bronchiectasis, but it suggests that fungal sensitisation may identify a subgroup needing closer assessment.
Can ABPA cause bronchiectasis?
The relationship between ABPA and bronchiectasis is complex.
Bronchiectasis may make it easier for Aspergillus to remain in the airways, increasing the opportunity for an allergic immune response. However, repeated Aspergillus-driven inflammation in ABPA may also damage the airways and contribute to bronchiectasis.
Recent research suggests that ABPA may contribute to bronchiectasis in some susceptible people, particularly when there is prolonged allergic inflammation and mucus plugging. However, not every person with ABPA develops bronchiectasis, and not every person with bronchiectasis has ABPA.
Symptoms can overlap
Bronchiectasis and Aspergillus-related disease may all cause:
- cough
- breathlessness
- wheeze
- fatigue
- increased sputum
- repeated chest infections
- reduced exercise tolerance
This overlap can make it difficult to know whether symptoms represent a usual fluctuation, a bacterial infection, ABPA, Aspergillus bronchitis, CPA or a combination of conditions.
Further assessment may be useful when symptoms are unusually persistent, severe or different from previous exacerbations.
How might doctors investigate Aspergillus-related disease?
Assessment usually combines several types of information:
- symptoms and their pattern over time
- the frequency and severity of exacerbations
- chest X-rays and CT scans
- sputum cultures and other microbiology
- Aspergillus-specific IgE and IgG blood tests
- total IgE and eosinophil counts
- lung-function testing
- occasionally bronchoscopy
Read more about how aspergillosis is diagnosed.
Aspergillus-specific IgG may support a diagnosis of CPA or Aspergillus bronchitis. Aspergillus-specific IgE and total IgE are more relevant when ABPA is suspected.
A positive blood test does not automatically prove active disease. Test results need to be interpreted with symptoms, imaging and sputum findings.
Why CT scans are important
CT scans can show the pattern and extent of bronchiectasis and may identify additional findings such as:
- mucus plugging
- high-attenuation mucus
- nodules
- cavities
- thickening around cavities
- changes suggesting a fungal ball
A CT scan may help distinguish established bronchiectasis from new changes that require further investigation. Read more about CT scans and aspergillosis.
When should someone with bronchiectasis seek further assessment?
Speak to your healthcare team if you have bronchiectasis and develop:
- a clear change in your usual cough or sputum
- repeated exacerbations or chest infections
- symptoms that do not respond as expected to antibiotics
- new or worsening wheeze
- unexplained weight loss or fatigue
- new changes on a chest X-ray or CT scan
- repeated courses of steroids
- coughing up blood
These symptoms do not necessarily mean that you have aspergillosis. They may be caused by bronchiectasis, bacteria, viruses, asthma or other conditions. The purpose of further assessment is to identify the cause accurately.
How is treatment decided?
Treatment depends on which Aspergillus-related condition is present.
- Aspergillus sensitisation may require monitoring and treatment of associated airway disease rather than antifungal medication.
- ABPA may require corticosteroids, antifungal treatment or other specialist therapies.
- Aspergillus bronchitis may be considered for antifungal treatment when symptoms and microbiology support the diagnosis.
- CPA may require prolonged antifungal treatment and careful monitoring.
Airway clearance, vaccination, treatment of bacterial infections and management of the underlying bronchiectasis remain important regardless of whether Aspergillus is detected.
Antifungal medicines can interact with inhalers, corticosteroids and other medicines, so they should only be started under appropriate medical supervision.
Key message: Bronchiectasis makes it harder to clear mucus and inhaled particles, which may increase vulnerability to several Aspergillus-related conditions. Most people with bronchiectasis will not develop active aspergillosis, but persistent or unusually severe symptoms may justify assessment for Aspergillus sensitisation, ABPA, Aspergillus bronchitis or CPA.
Related information
- Understanding chronic pulmonary aspergillosis
- Aspergillus bronchitis
- Allergic bronchopulmonary aspergillosis
- How aspergillosis is diagnosed
- Understanding Aspergillus blood tests
- Mucus clearance techniques
- Diseases associated with aspergillosis
Further reading
Recent review: Agarwal R, Chotirmall SH, Chalmers JD.
Allergic bronchopulmonary aspergillosis and Aspergillus-related airway diseases in bronchiectasis: a narrative review.
Journal of Thoracic Disease. 2025;17:11501–11519.
Read the review on PubMed
Recent research: Tiew PY, Narayana JK, Jaggi TK, et al.
Aspergillus fumigatus sensitization is associated with high-risk bronchiectasis.
Chest. 2026;169:932–946.
Further discussion: Agarwal R, Sehgal IS, Muthu V, Bardin P.
Does ABPA contribute to bronchiectasis? A structured evaluation of competing hypotheses.
Clinical & Experimental Allergy. 2026;56:498–505.
Read the paper
This information is for education and should not replace advice from your own healthcare team.
COPD and Aspergillosis: Understanding the Connection

Chronic obstructive pulmonary disease (COPD) and aspergillosis are separate conditions, but they can sometimes occur together. COPD can damage the airways and lung tissue, making it more difficult to clear inhaled Aspergillus spores.
Most people with COPD will not develop aspergillosis. However, Aspergillus-related disease may be overlooked because its symptoms can resemble a COPD flare-up or a chest infection.
What is COPD?
Chronic obstructive pulmonary disease (COPD) is a long-term condition in which airflow through the lungs becomes restricted. The obstruction usually develops gradually and may become more noticeable over time.
COPD mainly includes two overlapping types of lung damage:
- Chronic bronchitis: long-term inflammation of the airways, often with increased mucus production and a persistent cough.
- Emphysema: damage to the small air sacs in the lungs, reducing the area available for oxygen to pass into the blood.
Many people have features of both. COPD can also cause narrowing of the smaller airways, trapping of air and difficulty clearing mucus from the lungs.
Symptoms may include:
- breathlessness, especially during activity
- a persistent cough
- regular production of sputum
- wheezing or chest tightness
- repeated chest infections
- reduced exercise tolerance
- fatigue
Symptoms may remain fairly stable for long periods, but can suddenly worsen during an exacerbation. An exacerbation may be triggered by a viral or bacterial infection, air pollution, smoke, cold weather or other factors.
COPD is often associated with smoking, but it can also result from long-term exposure to air pollution, occupational dusts and fumes, previous infections, childhood lung problems or genetic conditions such as alpha-1 antitrypsin deficiency.
COPD is not contagious. It is also not simply an inevitable part of getting older. Diagnosis usually involves a medical history, examination and breathing tests such as spirometry.
What is aspergillosis?
Aspergillosis describes several different conditions caused by Aspergillus, a common mould found in soil, dust, compost and the air.
Most people breathe in Aspergillus spores without becoming ill. Problems are more likely when a person has damaged lungs, an altered immune response or treatment that suppresses immunity.
Relevant forms of disease include:
- chronic pulmonary aspergillosis (CPA)
- aspergilloma, sometimes called a fungal ball
- Aspergillus bronchitis
- allergic bronchopulmonary aspergillosis (ABPA)
- invasive pulmonary aspergillosis
These conditions are different and require different investigations and treatments.
Why can COPD increase the risk of aspergillosis?
COPD can affect the lungs in several ways that may increase vulnerability to Aspergillus:
- damaged airways may clear mucus and inhaled particles less effectively
- emphysema can create areas of structurally abnormal lung
- previous infections may leave scars or cavities
- repeated exacerbations can increase inflammation and lung damage
- corticosteroid treatment can alter the immune response
The risk is not caused by COPD alone. It depends on the severity and type of lung damage, previous infections, smoking history, immune function, steroid exposure and other health conditions.
New research: Aspergillus allergy and sensitisation in COPD
A 2026 systematic review and meta-analysis examined allergic bronchopulmonary aspergillosis (ABPA) and Aspergillus sensitisation in people with COPD. The researchers combined evidence from 23 studies involving more than 5,000 people.
They estimated that:
- approximately 2.1% of people with COPD had ABPA
- approximately 10.4% had evidence of sensitisation to Aspergillus
These findings suggest that Aspergillus-related allergy may occur in COPD more often than previously recognised. However, sensitisation is not the same as active infection or ABPA. A positive allergy or blood test does not automatically mean that treatment is needed.
The findings support a more careful assessment of people with COPD who have unexplained wheezing, difficult-to-control symptoms, recurrent exacerbations or features suggesting an allergic fungal response.
Read our summary of the 2026 COPD and Aspergillus review.
Chronic pulmonary aspergillosis and COPD
CPA is a long-term fungal lung infection that usually develops in areas of existing lung damage. It may cause cavities, thickening around cavities, nodules or progressive changes in the lungs.
Symptoms of CPA can include:
- persistent cough
- increasing breathlessness
- fatigue
- weight loss
- night sweats or a low-grade fever
- persistent or increasing sputum
- coughing up blood
These symptoms can also occur during COPD exacerbations, which makes diagnosis difficult. Symptoms that continue after the usual treatment for a COPD flare-up may need further investigation.
Could Aspergillus be contributing to repeated COPD flare-ups?
Not every COPD exacerbation is caused by Aspergillus. Bacteria, viruses, pollution, smoking, weather changes and other factors can all trigger worsening symptoms.
However, Aspergillus may sometimes be involved when a person has:
- frequent or unusually severe exacerbations
- symptoms that do not respond as expected to antibiotics or inhalers
- persistent chest symptoms between exacerbations
- unexplained weight loss or fatigue
- new cavities, nodules or other changes on a CT scan
- recurrent haemoptysis
- a history of tuberculosis or another condition causing structural lung damage
Research has also found Aspergillus in the airways of some people with COPD without proving that it is causing active disease. Detection of Aspergillus therefore needs to be interpreted alongside symptoms, imaging and other test results.
Why steroids need careful balancing
Corticosteroids may be prescribed during COPD exacerbations and, in some people, as part of regular inhaled treatment. They can reduce airway inflammation and improve symptoms.
However, corticosteroids can also affect the immune response that helps control Aspergillus. Recent research has reported an association between corticosteroid exposure and pulmonary aspergillosis, with higher exposure associated with greater risk.
This does not mean that people with COPD should stop their inhalers or avoid steroids when they are medically necessary. Treatment should only be changed with advice from a healthcare professional.
The important point is that repeated or prolonged steroid treatment, particularly when symptoms are not improving as expected, may be one reason to review the diagnosis and consider whether fungal disease or another infection is contributing. Read more about steroids, aspergillosis and the immune system.
How might doctors investigate aspergillosis?
There is no single test that diagnoses every form of aspergillosis. Assessment may include:
- symptoms and how long they have been present
- previous chest imaging and a current CT scan
- lung-function testing
- Aspergillus-specific IgG blood testing
- total IgE and Aspergillus-specific IgE when ABPA is suspected
- sputum culture, PCR or other microbiology
- occasionally bronchoscopy
Read more about how aspergillosis is diagnosed.
An Aspergillus IgG blood test can provide evidence of a longer-term immune response to Aspergillus and is often useful when CPA is being considered. However, a positive result does not prove active CPA by itself.
CT scans may help identify cavities, nodules, fibrosis, emphysema, mucus plugging or other changes that are difficult to see on a chest X-ray. Read more about why CT scans are used in aspergillosis.
When should someone with COPD seek further assessment?
Speak to your healthcare team if you have COPD and develop:
- breathlessness that is worsening or different from usual
- a cough that does not settle after an exacerbation
- persistent or increasing sputum
- unexplained weight loss or fatigue
- repeated courses of antibiotics or steroids
- new abnormalities on a chest X-ray or CT scan
- coughing up blood
These symptoms do not necessarily mean that you have aspergillosis. They may result from COPD itself, infection, heart disease, medication effects or other causes. The purpose of further assessment is to identify the cause accurately so that treatment can be chosen appropriately.
Key message: Most people with COPD will not develop aspergillosis. However, COPD-related lung damage, repeated exacerbations and corticosteroid exposure may increase susceptibility. If symptoms are unusually persistent, severe or difficult to explain, Aspergillus-related disease may need to be considered alongside the more common causes of COPD deterioration.
Related information
- Understanding chronic pulmonary aspergillosis
- How aspergillosis is diagnosed
- Understanding Aspergillus blood tests
- Steroids and the immune system
- Diseases associated with aspergillosis
Further reading
Recent systematic review: Ajayababu A, Antony A, Goyal B, Ray A.
Prevalence of allergic bronchopulmonary aspergillosis/Aspergillus sensitization in chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Respiratory Investigation. 2026.
Read the paper on PubMed
Clinical overview: Otu A, et al.
The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease.
Infection. 2023;51:813–829.
Clinical guidance: The British Thoracic Society has published a clinical statement on
Aspergillus-related chronic lung disease
This information is for education and should not replace advice from your own healthcare team.
Sarcoidosis and Aspergillosis: Understanding an Important Connection

Sarcoidosis and aspergillosis are different conditions, but they can sometimes occur in the same person. The relationship is most important when sarcoidosis has caused lasting damage to the lungs, including scarring, fibrosis or cavities.
This does not mean that everyone with sarcoidosis will develop aspergillosis. Most people with sarcoidosis do not. However, when symptoms or lung changes worsen, it is important not to assume automatically that sarcoidosis is becoming more active.
What is sarcoidosis?
Sarcoidosis is an inflammatory condition in which groups of immune cells form small areas of inflammation called granulomas. It can affect several parts of the body, but the lungs and lymph nodes in the chest are most commonly involved.
Some people have few or no symptoms. Others may experience:
- breathlessness
- a persistent cough
- chest discomfort
- fatigue
- reduced exercise tolerance
- weight loss or a general feeling of being unwell
In some people, inflammation settles without causing permanent damage. In others, long-term inflammation can lead to scarring and changes in the structure of the lungs.
Why can sarcoidosis increase the risk of aspergillosis?
Chronic pulmonary aspergillosis (CPA) is a long-term lung infection caused by Aspergillus, a mould that is commonly found in the environment and is breathed in regularly by most people. You can read more about the different forms of CPA.
Healthy lungs usually clear inhaled Aspergillus spores without difficulty. However, damaged or scarred lung tissue can make it easier for Aspergillus to persist and grow.
Advanced pulmonary sarcoidosis may cause:
- fibrosis and scarring
- distortion of the airways
- areas of poorly functioning lung
- cavities or spaces within the lungs
These changes may create conditions in which chronic pulmonary aspergillosis or an aspergilloma can develop. An aspergilloma, sometimes called a fungal ball, is a collection of fungal material that grows within an existing lung cavity.
The risk is not caused by sarcoidosis alone. It reflects a combination of factors, including the amount and type of lung damage, the immune response, exposure to Aspergillus and treatments such as corticosteroids or other immunosuppressive medicines.
How common is the association?
The relationship between sarcoidosis and chronic pulmonary aspergillosis is clinically important, but it remains relatively understudied. A 2026 review reported that approximately 2% of people with sarcoidosis developed CPA in some recent tertiary-care cohorts.
Older studies involving people with more advanced fibrocystic sarcoidosis reported higher estimates, between 3% and 12%. These figures are not directly comparable because specialist centres tend to see more people with severe and complicated disease.
The available evidence does not suggest that sarcoidosis commonly or inevitably leads to aspergillosis. Instead, risk appears to result from several factors acting together:
- fibrosis, cavities or other structural lung damage
- changes in local and general immune function
- regular exposure to Aspergillus in the environment
- corticosteroid or other immunosuppressive treatment
Symptoms can overlap
One of the difficulties is that sarcoidosis and chronic pulmonary aspergillosis can cause similar symptoms. These may include:
- increasing breathlessness
- persistent or worsening cough
- fatigue
- weight loss
- reduced lung function
- declining ability to exercise
- changes visible on chest X-rays or CT scans
This overlap can make it difficult to tell whether symptoms are caused by active sarcoidosis, permanent lung damage, chronic infection, or more than one condition at the same time.
Blood in the sputum, known as haemoptysis, can occur with several lung conditions. It may also occur when an aspergilloma or CPA affects blood vessels in damaged lung tissue. Any new or significant haemoptysis should be discussed promptly with a healthcare professional.
Why scans may need careful interpretation
Chest imaging is an important part of assessing both sarcoidosis and aspergillosis. A CT scan may show fibrosis, nodules, cavities, thickening around cavities or changes in existing areas of lung damage.
Some of these findings can be seen in advanced sarcoidosis as well as CPA. A single scan does not always provide the complete answer. Doctors may need to compare scans over time and consider:
- whether existing cavities or scars are changing
- whether new cavities or nodules have appeared
- whether there is thickening around a cavity
- whether a fungal ball is present
- how scan findings relate to symptoms and lung-function results
The overall pattern, and how it changes over time, is often more useful than one isolated scan finding. Read more about why CT scans are used in aspergillosis.
The challenge of steroid treatment
Corticosteroids are often used to control inflammation caused by sarcoidosis. Other immunosuppressive medicines may also be used when sarcoidosis affects the lungs or other organs.
These treatments can be very important and should not be stopped suddenly or changed without medical advice. However, corticosteroids and some other immunosuppressive medicines can reduce the body's ability to control infection.
If chronic pulmonary aspergillosis is present but not recognised, increasing immunosuppression may allow the infection to become more active. This is one reason why unexpected deterioration, new radiological changes or symptoms that do not respond as expected should be assessed carefully before assuming that sarcoidosis is the only cause.
This does not mean that steroids are always unsafe for people with sarcoidosis. The decision is individual and may involve balancing inflammation, infection risk, lung damage and other health needs. Read more about steroids, aspergillosis and the immune system.
What does recent research show?
A 2026 review concluded that CPA occurs mainly when sarcoidosis has caused substantial structural lung damage, particularly fibrosis or cavities. The authors described the association as clinically important but relatively understudied.
In a study of 65 people with CPA complicating sarcoidosis, almost all had advanced fibrocystic pulmonary disease. Chronic cavitary pulmonary aspergillosis was the most common form of CPA. The factors most strongly associated with outcome were the extent of fibrosis, reduced overall lung function and pulmonary hypertension.
The study also found that poor outcomes were more often related to advanced sarcoidosis and the resulting loss of lung function than to aspergillosis alone. This is important because it shows that CPA is part of a complex picture rather than necessarily being the only cause of deterioration.
These findings help explain why assessment needs to consider the whole clinical picture. A change in symptoms or a scan may reflect active sarcoidosis, permanent lung damage, CPA or a combination of these conditions.
How might doctors investigate aspergillosis?
There is no single test that diagnoses every form of aspergillosis. Doctors usually combine several types of information, including:
- symptoms and how they have changed
- previous CT scans and current imaging
- lung-function tests
- blood tests for Aspergillus-specific antibodies, particularly Aspergillus IgG
- sputum testing for Aspergillus and other organisms
- occasionally bronchoscopy or other specialised tests
Blood tests for Aspergillus-specific IgG may support the diagnosis of CPA. However, a positive result does not prove by itself that active infection is present. It must be interpreted alongside symptoms, imaging and other test results.
Doctors may also use sputum testing, lung-function tests and, occasionally, bronchoscopy. Read more about how aspergillosis is diagnosed.
The 2026 review emphasised that diagnosis usually depends on combining imaging, Aspergillus-specific IgG and microbiological evidence with evidence of clinical progression.
Why specialist review may be helpful
Managing sarcoidosis and CPA together can be complicated. Treatment for sarcoidosis may involve corticosteroids or other medicines that suppress inflammation, while CPA may require prolonged antifungal treatment.
These medicines can interact with each other, and antifungal treatment may require monitoring for side effects, liver problems and drug levels. Some patients may need long-term antifungal treatment, particularly if disease is progressive or returns after treatment is stopped.
For this reason, unexpected deterioration, new cavities, progressive changes on CT, persistent systemic symptoms or haemoptysis may require discussion between respiratory, sarcoidosis and fungal-disease specialists.
What does this mean for someone with sarcoidosis?
Having sarcoidosis does not mean that you will develop aspergillosis. The association is most relevant in people with significant structural lung damage, particularly fibrosis or cavities.
It is worth telling your healthcare team if you develop:
- new or worsening breathlessness
- a persistent change in your cough
- unexplained weight loss or worsening fatigue
- repeated chest infections
- new changes on a chest X-ray or CT scan
- coughing up blood
- symptoms that continue despite treatment for sarcoidosis
These symptoms can have many causes, and they do not necessarily mean that you have aspergillosis. They simply deserve appropriate assessment rather than being automatically attributed to sarcoidosis.
Key message: Sarcoidosis and aspergillosis are separate conditions, but advanced sarcoidosis can sometimes cause lung changes in which chronic pulmonary aspergillosis develops. Most people with sarcoidosis will not develop CPA. When symptoms or scans change unexpectedly, considering both inflammation and infection can help doctors choose the safest treatment.
Related information
- Understanding chronic pulmonary aspergillosis
- How aspergillosis is diagnosed
- Understanding Aspergillus blood tests
- Diseases associated with aspergillosis
- Steroids and the immune system
Further reading
Recent review:
Jeny F, Brun S, Tran Ba S, Uzunhan Y.
Chronic pulmonary aspergillosis and sarcoidosis.
Current Opinion in Pulmonary Medicine, 2026.
Read the review on PubMed
.
Clinical study:
Uzunhan Y, Nunes H, Jeny F, et al.
Chronic pulmonary aspergillosis complicating sarcoidosis.
European Respiratory Journal. 2017;49:1602396.
Read the study on the ERS website
.
Earlier cohort and literature review:
Pena TA, Soubani AO, Samavati L.
Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature.
Lung. 2011;189:167–172.
Read the article information
.
This information is for education and should not replace advice from your own healthcare team.
Tuberculosis and Aspergillosis: Why Lung Symptoms Can Continue After TB Treatment

Most people who complete treatment for pulmonary tuberculosis do not develop aspergillosis. However, TB can leave cavities, scarring and widened airways in the lungs. These structural changes sometimes allow Aspergillus to grow and cause chronic pulmonary aspergillosis (CPA).
TB and chronic pulmonary aspergillosis can cause remarkably similar symptoms and changes on chest imaging. This means that aspergillosis may be mistaken for recurrent TB, treatment failure or simply permanent damage left by the original infection.
Recognising the connection is particularly important when cough, breathlessness, weight loss, fatigue or coughing up blood continue or return after apparently successful TB treatment.
What is pulmonary tuberculosis?
Tuberculosis (TB) is an infection caused by bacteria belonging to the Mycobacterium tuberculosis group. It can affect several parts of the body, but pulmonary TB affects the lungs.
Active pulmonary TB can cause inflammation and destroy areas of lung tissue. Treatment can remove the active bacteria, but it cannot always reverse the structural damage that has already occurred.
Changes remaining after treatment may include:
- scarring and fibrosis;
- persistent spaces or cavities within the lungs;
- bronchiectasis, in which damaged airways become widened;
- thickening of the lining around the lungs;
- reduced lung volume or distortion of the airways;
- impaired mucus clearance.
These changes are collectively described as part of post-tuberculosis lung disease. They can cause long-term symptoms even when no active TB bacteria remain.
How can previous TB lead to aspergillosis?
Aspergillus is a common mould found in soil, compost, dust and the air around us. Most people inhale its microscopic spores regularly without becoming ill.
A healthy lung usually clears the spores effectively. However, a cavity left by pulmonary TB provides an abnormal space in which Aspergillus may settle and grow.
This can lead to several different problems:
- Aspergilloma: a fungal ball that forms inside an existing lung cavity.
- Chronic cavitary pulmonary aspergillosis: one or more cavities that persist or gradually enlarge, sometimes containing a fungal ball.
- Chronic fibrosing pulmonary aspergillosis: extensive scarring and destruction that can develop when chronic disease progresses.
- Aspergillus nodules: one or more rounded abnormalities that may resemble cancer or another infection on a scan.
These forms sit within the spectrum known as chronic pulmonary aspergillosis.
Post-TB bronchiectasis may also impair mucus clearance and make the lungs more vulnerable to repeated bacterial or fungal infection.
Does everyone who has had TB need to worry?
No. Most people treated for TB will not develop CPA.
The risk is greater when pulmonary TB has left substantial structural damage, particularly one or more persistent cavities. Other factors may include:
- bronchiectasis;
- COPD or emphysema;
- low body weight or poor nutrition;
- diabetes;
- immune suppression;
- long-term or repeated corticosteroid treatment;
- more than one episode of pulmonary TB.
Latent TB—where TB bacteria are present without active disease—does not usually produce the same lung cavities and is not equivalent to having had destructive pulmonary TB.
Why are TB and CPA easily confused?
The two conditions share several possible symptoms:
- a persistent cough;
- increasing breathlessness;
- fatigue;
- weight loss or difficulty regaining weight;
- fever or night sweats;
- chest discomfort;
- coughing up blood (haemoptysis).
Both can also produce cavities, scarring and areas of inflammation on chest X-rays or CT scans.
When symptoms recur after TB treatment, it is therefore understandable that recurrent TB may be suspected first. In countries where TB is common but fungal diagnostic tests are difficult to obtain, some people may receive further courses of anti-TB treatment without convincing evidence that active TB has returned.
However, TB medicines do not treat Aspergillus. Delayed recognition allows CPA to continue damaging the lungs.
Can active TB and aspergillosis occur together?
Yes. Although CPA often becomes apparent after TB treatment, active TB and Aspergillus-related disease can occasionally coexist.
Finding evidence of one condition therefore does not always exclude the other. Clinicians may need to investigate for both, particularly when:
- symptoms or imaging do not improve as expected;
- TB tests are repeatedly negative despite continuing symptoms;
- the patient initially improves but then deteriorates;
- there is a persistent cavity or a possible fungal ball;
- significant coughing of blood develops.
Coexisting disease can make treatment more complicated. Rifampicin and some other TB medicines interact strongly with azole antifungal medicines, so treatment must be planned and monitored by clinicians experienced in managing these interactions.
When should CPA be considered after TB?
Further assessment may be appropriate when respiratory or constitutional symptoms persist for several months, return after treatment or gradually worsen—especially in someone with cavities or other substantial changes on lung imaging.
Symptoms warranting discussion with a healthcare professional include:
- a cough that does not settle;
- gradually worsening breathlessness;
- ongoing or unexplained fatigue;
- unintentional weight loss;
- recurrent chest infections;
- blood in the sputum;
- new or enlarging cavities on imaging.
These symptoms have many possible causes. They do not prove that CPA is present, but they should not automatically be attributed to old TB damage without considering other explanations.
How is chronic pulmonary aspergillosis diagnosed?
There is no single test that diagnoses every case. Clinicians combine the person’s history, symptoms, imaging and laboratory results. You can find a broader explanation on our diagnosis of aspergillosis page.
Chest imaging
A CT scan provides much more detail than a chest X-ray. Features that may raise suspicion include:
- one or more lung cavities;
- a cavity that is enlarging or developing a thicker wall;
- a fungal ball within a cavity;
- thickening around the cavity or lining of the lung;
- new areas of inflammation around an old cavity;
- progressive fibrosis or loss of lung volume;
- one or more nodules.
Comparison with older images is extremely valuable. A single abnormal scan may show the damage left by TB, but scans taken over time can reveal whether the disease is stable or progressing.
Aspergillus IgG blood testing
An Aspergillus IgG antibody test is one of the most useful blood tests for CPA. A positive result indicates that the immune system has made a significant response to Aspergillus.
The result must be interpreted alongside symptoms and imaging. A positive result alone does not prove active CPA, while a negative result does not exclude every case, particularly in someone whose immune system cannot produce a strong antibody response.
Sputum testing
Sputum may be tested using fungal culture or molecular techniques such as PCR. Finding Aspergillus supports the diagnosis, but cultures are often negative even when CPA is present.
A negative sputum culture should therefore not be used by itself to rule out CPA.
Sputum should also be tested for TB and, where appropriate, other bacteria or nontuberculous mycobacteria. More than one infection may be present.
Other investigations
Depending on the individual case, clinicians may use:
- lung-function testing;
- bronchoscopy and samples from the lower airways;
- biopsy of a nodule or other abnormal area;
- tests for other fungal infections found in particular parts of the world;
- assessment for lung cancer or another cause of cavitation.
How is CPA treated?
Treatment depends on the form and severity of disease, the person’s symptoms, whether imaging is progressing and their other medical conditions.
Oral antifungal medicines such as itraconazole or voriconazole are commonly used. Posaconazole or isavuconazole may be considered in some circumstances. Treatment frequently continues for many months and sometimes longer.
Monitoring is important because antifungal medicines can:
- interact with other medicines;
- affect the liver or cause other adverse effects;
- produce blood levels that are too low or too high;
- be ineffective if the infecting Aspergillus is resistant.
Blood tests, antifungal drug-level measurements and follow-up imaging may therefore be required. Read more about drug interactions with antifungal medicines.
A single stable aspergilloma without significant symptoms may sometimes be monitored rather than treated immediately. Surgery may be considered in selected patients with a localised fungal ball and adequate lung function. Significant bleeding may require urgent treatment, including a procedure to block the responsible blood vessel.
Why does earlier recognition matter?
Untreated CPA can gradually enlarge lung cavities, increase fibrosis and further reduce lung function. It can also cause severe or recurrent bleeding.
Earlier diagnosis offers several potential benefits:
- avoiding unnecessary repeat courses of TB medication;
- starting appropriate antifungal treatment when needed;
- monitoring cavities before extensive damage develops;
- identifying other causes of persistent symptoms;
- improving recognition of post-TB lung disease more broadly.
Not every person who has completed TB treatment needs extensive fungal testing. A more practical approach is to investigate people with persistent or recurrent symptoms, residual cavities or unexplained progression on imaging.
The global diagnostic gap
TB affects millions of people worldwide, particularly in countries where access to CT scanning, Aspergillus IgG testing and specialist fungal services may be limited.
Recent research has confirmed a substantial burden of CPA among people previously treated for TB. However, estimates vary widely between studies because the populations, diagnostic tests and definitions differ.
This is not simply a problem in countries with a high TB incidence. People may move between countries many years after treatment, and CPA can emerge or be recognised long after the original infection.
A history of pulmonary TB remains clinically relevant even if treatment took place decades earlier.
Healthcare professionals can read our specialist evidence summary on CPA during tuberculosis treatment for a more detailed discussion of recent research and diagnostic pathways.
What should patients do?
If you have previously been treated for pulmonary TB and continue to experience respiratory symptoms:
- tell your clinician about the previous TB, even if it occurred many years ago;
- ask whether old and current scans have been compared;
- ask whether cavities, bronchiectasis or substantial scarring remain;
- discuss whether Aspergillus IgG and sputum testing would be appropriate;
- seek prompt advice if you cough up blood;
- do not stop or alter TB or antifungal medication without medical advice.
Coughing up more than a few streaks or spots of blood, or bleeding accompanied by breathlessness, dizziness or weakness, requires urgent medical assessment. Call emergency services if the bleeding is substantial.
For more detailed information about recognising and responding to bleeding, see our patient guide to haemoptysis.
Key points
- Pulmonary TB can leave cavities, scarring and bronchiectasis even after the infection has been successfully treated.
- These structural changes can increase susceptibility to chronic pulmonary aspergillosis.
- TB and CPA can both cause cough, weight loss, fatigue, breathlessness, bleeding and lung cavities.
- CPA may be mistaken for recurrent TB or dismissed as permanent post-TB damage.
- Diagnosis usually requires a combination of CT imaging, Aspergillus IgG testing and microbiological evidence.
- A negative sputum fungal culture does not exclude CPA.
- Most people treated for TB do not develop CPA, but persistent or worsening symptoms deserve investigation.
Further information and evidence
- Systematic review of chronic pulmonary aspergillosis among people treated for pulmonary tuberculosis
- British Thoracic Society Clinical Statement on Aspergillus-related chronic lung disease
- World Health Organization: global burden of CPA following pulmonary tuberculosis
- Prospective study of CPA following tuberculosis in Nigeria
This article provides general information and does not replace assessment by a TB, respiratory or fungal-infection specialist.
Dehumidifiers: How to Reduce Damp, Condensation and Mould Safely

How to choose, use and clean a dehumidifier safely—and understand what it can and cannot do about damp and mould
Dehumidifiers can be useful when excess moisture is building up inside a home. They can reduce condensation, help laundry dry indoors and make it harder for mould to grow.
However, a dehumidifier is not a complete solution to every damp problem. It removes water from the air; it does not repair a leaking roof or pipe, stop rain entering through a wall, correct rising damp, insulate a cold surface or provide fresh air.
Quick answer
- Use an inexpensive digital hygrometer to measure relative humidity.
- A practical target for most homes is approximately 40–55% relative humidity.
- Try to prevent humidity remaining above 60%, where condensation and mould become more likely.
- Do not try to make the air extremely dry: prolonged humidity below about 30% may irritate the eyes, skin and airways.
- Choose a unit appropriate for the room temperature and size—not simply the largest number printed on the box.
- Empty and clean the water tank and filter regularly so that the appliance itself does not become contaminated.
Contents
- Where does indoor moisture come from?
- Find the cause before buying a dehumidifier
- What humidity should I aim for?
- When is a dehumidifier helpful?
- Compressor, desiccant or mini dehumidifier?
- How to choose a suitable model
- How to use it effectively
- Cleaning and preventing fungal growth
- How to calculate the running cost
- What does this mean for someone with aspergillosis?
- If you rent your home
Where Does Indoor Moisture Come From?
Moisture is continually added to indoor air by ordinary activities, including:
- breathing and perspiration
- showering and bathing
- cooking and boiling water
- drying washing indoors
- unvented tumble dryers
- paraffin or portable bottled-gas heaters
- aquariums and large numbers of houseplants
- water entering through leaks or defects in the building
Warm air can contain more water vapour than cold air. When warm, moist air meets a cold window, outside wall or other cold surface, some of that water may condense. This is why dripping windows and mould in cold corners are often most noticeable during winter.
Find the Cause Before Buying a Dehumidifier
Different forms of damp require different solutions.
| Likely problem | Typical clues | What is needed? |
|---|---|---|
| Condensation | Water on windows; mould in corners, behind furniture or on cold outside walls; worse during cold weather or after cooking, showering or drying laundry. | Reduce moisture production, improve ventilation and heating, address cold surfaces and consider a dehumidifier. |
| Penetrating damp or a leak | A localised wet patch, staining, damaged plaster or worsening after rain; possible leaking roof, gutter, pipe or window. | Repair the source of water. A dehumidifier may help the structure dry afterwards but cannot repair the fault. |
| Rising damp | Damp and salts low down on ground-floor or basement walls, sometimes with a visible tide mark. | Professional investigation and appropriate building repair. |
| Construction moisture | A new building, extension, plastering or other recent wet building work. | Time, appropriate heat and ventilation; a suitable dehumidifier may speed drying. |
If water is entering the property, the priority is to stop it. Continuously operating a dehumidifier while a leak remains is like emptying a bath while leaving the tap running.
A dehumidifier does not replace ventilation. It removes water from existing indoor air but does not remove carbon dioxide, cooking pollutants, odours or other contaminants, and it does not bring fresh air into the home.
What Humidity Should I Aim For?
Relative humidity—usually shown as % RH—describes how much water vapour the air contains relative to the maximum it could contain at that temperature.
NHS advice recommends keeping indoor humidity between 40% and 60%. For a home with recurring condensation or for someone trying to reduce conditions favourable to mould, a practical operating target is often around 45–55%.
- Repeatedly above 60%: investigate moisture production, ventilation, heating, cold surfaces and building defects.
- Around 40–55%: a useful practical range for many occupied homes.
- Below 30% for long periods: may be unnecessarily dry and can irritate airways, skin and eyes.
A small digital hygrometer is more useful than guessing. Place it away from radiators, windows, direct sunlight and the dehumidifier’s air outlet. If possible, move it between rooms or use more than one to identify where and when humidity rises.
Remember that relative humidity changes with temperature. A cold wall may still develop surface condensation even when the centre of the room appears acceptable.
When Is a Dehumidifier Helpful?
A dehumidifier may be useful:
- when condensation persists despite reasonable heating and ventilation
- in a basement or other area where effective ventilation is difficult
- while drying laundry indoors, particularly when outdoor drying is impossible
- after a leak or flood has been repaired
- during humid weather when opening windows does not lower indoor humidity
- as a temporary measure while a landlord or contractor investigates the underlying problem
On a dry day, opening windows and using extractor fans may remove moisture more cheaply while also improving air quality. On a very humid day, bringing outdoor air inside may not lower the humidity, so a hygrometer can help you judge what works.
A dehumidifier will not remove mould that is already growing. Existing mould and its underlying moisture source still need to be dealt with safely.
Compressor, Desiccant or Mini Dehumidifier?
| Type | Usually best for | Important limitations |
|---|---|---|
| Compressor or refrigerant | Heated living spaces. These cool humid air so that water condenses into a tank. | Performance falls in colder rooms, and the unit may need to pause for defrosting. Usually heavier and contains refrigerant. |
| Desiccant | Cooler spaces such as an unheated room, garage, boat or conservatory. An absorbent material captures moisture. | Often uses more electricity, although the warm outlet air can be useful in a cold space. |
| Thermoelectric or Peltier mini unit | A very small enclosed space with a minor moisture problem. | Removes far less water than a full-sized unit and is unlikely to control serious room-scale condensation. |
| Disposable moisture absorber | A cupboard, wardrobe or similarly small enclosed space. | Not a substitute for an electric dehumidifier in a damp room or home. The collected liquid also needs careful handling. |
For most normally heated UK bedrooms and living rooms, a compressor model is usually the starting point. A desiccant model may be more effective if the space is consistently cold.
How to Choose a Suitable Model
Do not rely on the advertised litres per day alone
Extraction figures are commonly measured under warm and very humid test conditions. A machine advertised as removing 12 or 20 litres per day will usually collect much less in an ordinary UK home, especially in a cooler room.
Use the manufacturer’s recommended room size as a starting point, but also consider how cold the space is, how severe the moisture problem is and whether you are trying to dry laundry. A very small machine may run continuously without ever reaching the target humidity.
Useful features
- An adjustable humidistat: allows the unit to stop automatically when the chosen RH is reached.
- Automatic restart: useful after a brief power interruption, where appropriate.
- Automatic defrost: important for compressor units used in cooler rooms.
- A washable or replaceable air filter: check how easily it can be removed and cleaned.
- A visible tank and full-tank shut-off: reduces the risk of overflow.
- Continuous drainage: useful if the unit will operate for long periods and a safe drain is available.
- Appropriate noise level: particularly important for a bedroom or shared living space.
- Clear power consumption: compare watts as well as the purchase price.
- Laundry mode: useful, but normally means a higher fan speed and greater noise or electricity use.
Independent comparative testing can be more informative than the headline extraction figure because it may measure performance at both normal room temperature and colder conditions.
How to Use a Dehumidifier Effectively
- Read the manufacturer’s instructions. Required clearances, operating temperatures and drainage arrangements differ between models.
- Place it where air can circulate. Do not cover the inlet or outlet, press it against curtains or furniture, or put laundry directly over it.
- Use the humidistat. Start at approximately 50–55% RH rather than running continuously at the driest possible setting.
- Close windows and outside doors while actively dehumidifying a room. Otherwise, the machine may continually try to dry incoming outdoor air.
- Contain high-moisture activities. When drying laundry, use a suitable room, close its internal door and follow the appliance’s safety instructions.
- Continue to ventilate the home appropriately. Use bathroom and kitchen extractors and trickle vents to remove pollutants and moisture at source.
- Keep the building reasonably and evenly heated. Warmer surfaces are less likely to collect condensation.
- Move the unit only as instructed. Compressor models may need to remain upright for a period after transport before being switched on.
If one unit is being used for several rooms, it is often more effective to treat the worst room with the door closed and then move the unit, rather than expecting a small machine in a hallway to control an entire home.
Cleaning and Preventing Fungal Growth
A dehumidifier deliberately collects water and dust. If neglected, its tank or filter can become dirty and may support microbial growth.
- Empty the tank whenever it is full and do not leave collected water standing unnecessarily.
- Wash and dry the tank at the interval recommended by the manufacturer.
- Clean the air filter regularly—some housing guidance recommends checking it weekly during frequent use.
- Inspect the tank, float, drainage hose and accessible surfaces for slime, deposits or visible growth.
- If using continuous drainage, make sure the hose falls correctly to a suitable drain and cannot develop stagnant loops of water.
- Do not add fragrances, bleach, disinfectants or other chemicals to the tank unless the manufacturer specifically permits this.
- Before storing the machine, clean it and allow the tank and accessible components to dry fully.
For people with aspergillosis or another chronic lung condition: if the machine smells musty, contains visible mould or has inaccessible contamination, avoid running it and blowing air through it. Ask someone else to clean it safely according to the instructions, or seek advice from the manufacturer.
How to Calculate the Running Cost
Electricity prices change, so a fixed “cost per day” quickly becomes inaccurate. You can calculate the approximate cost from the appliance’s power rating:
Power in watts ÷ 1,000 × hours used × your electricity price per kWh
For example, a 300-watt machine used for eight hours consumes up to:
300 ÷ 1,000 × 8 = 2.4 kWh
Multiply 2.4 by the price per kWh shown on your electricity tariff. A humidistat will usually reduce consumption once the target humidity is reached, so actual use may be lower than this maximum calculation.
Compare machines by how much useful water they remove under realistic conditions, not wattage alone. A low-powered but ineffective unit that runs continuously may not be the cheapest option.
What Does This Mean for Someone With Aspergillosis?
Damp and mould are associated with respiratory health problems, and people with existing respiratory disease may be more vulnerable to their effects. Reducing persistent dampness and preventing mould growth is therefore sensible.
However:
- a dehumidifier does not treat aspergillosis
- it does not remove fungal growth already present in a building
- it cannot guarantee that airborne fungal exposure has been eliminated
- there is not enough evidence to promise that buying one will improve an individual patient’s symptoms or prevent a relapse
Its role is practical: controlling excess indoor moisture when that is part of the problem.
People with significant lung disease should avoid personally disturbing large or extensive areas of mould. Dry brushing or sanding can release particles into the air. The moisture source and necessary remediation should be assessed, and appropriate professional help may be needed.
If You Rent Your Home
Do not allow a supplied dehumidifier to become the landlord’s only response to a leaking, structurally damp, poorly insulated or inadequately ventilated property.
Government guidance for England states that landlords should identify and address the underlying causes of damp and mould rather than dismissing the problem as the result of a resident’s “lifestyle”. Report problems in writing, keep photographs and dates, and record any effects on health or damage to belongings.
For social housing in England, the first phase of Awaab’s Law has applied since 27 October 2025 and covers emergency hazards and significant damp-and-mould hazards. Rights and procedures differ elsewhere in the UK and internationally, so use the housing guidance for your location.
A dehumidifier may be a useful temporary safety measure while investigation and repair take place. It should not transfer responsibility for a defective building to the tenant.
Summary
A dehumidifier can reduce excess moisture and condensation when it is correctly sized, correctly used and properly cleaned. Aim for a measured indoor relative humidity of approximately 40–55%, and investigate readings that remain above 60%.
The best long-term solution is always to control moisture at source: repair leaks, use effective extraction and ventilation, avoid unnecessary moisture production, provide appropriate heating and address cold or poorly insulated surfaces.
Control the moisture, but also find out why it is there.
Further Reading and References
- NHS: Condensation, damp and mould
- UK Government: Understanding and addressing the health risks of damp and mould in the home
- Energy Saving Trust: Fixing damp and condensation
- Energy Saving Trust: How to improve your home’s ventilation
- UK Government: Awaab’s Law in the social rented sector
- Which?: How to buy the best dehumidifier
Last reviewed: August 2026.
Gardening Safely With Aspergillosis: Soil, Compost and Mould Exposure

How to enjoy gardens while reducing exposure to compost, soil, dust, mould spores and pollen
Gardening can provide gentle physical activity, enjoyment, purpose and valuable time outdoors. Having aspergillosis does not automatically mean that you must give it up.
However, Aspergillus is common in soil, compost and decaying vegetation. Activities that disturb these materials can release large numbers of spores and other particles into the air. The sensible approach is therefore to identify the highest-exposure jobs, adapt or delegate them, and take precautions suited to your individual health.
Quick guide
- Enjoy the garden, but reduce avoidable exposure.
- Avoid turning compost heaps, shredding decaying vegetation, using leaf blowers and opening dusty compost bags yourself.
- Never open or tip compost, bark, mulch or potting mix inside a greenhouse, shed or other enclosed space.
- Ask someone else to do the dustiest jobs whenever possible.
- If exposure cannot be avoided, use a well-fitting certified respirator—preferably FFP3 for high levels of mould spores—and understand its limitations.
- Wear gloves, cover cuts, wash your hands and change dusty clothing afterwards.
- If you are severely immunocompromised, ask your specialist team whether you should avoid soil and compost completely during the high-risk period.
Contents
- Why can gardening create an exposure?
- Does everyone with aspergillosis need the same precautions?
- Which gardening jobs create the most exposure?
- Lower-exposure ways to enjoy gardening
- Compost, potting mix, mulch and bark
- Choosing and using a mask
- Before, during and after gardening
- Greenhouses, sheds and enclosed spaces
- What about pollen and asthma?
- When should I seek medical advice?
Why Can Gardening Create an Exposure?
Aspergillus species occur naturally throughout the environment. They help break down dead plant material and are particularly associated with soil, compost, leaf litter, stored vegetation and other decomposing organic matter.
The fungus produces microscopic airborne spores. We all breathe some spores during everyday life, and completely avoiding them is impossible. Exposure can rise sharply, however, when contaminated material is disturbed.
Examples include:
- opening and tipping a bag of compost
- turning a warm compost heap
- sweeping a dry shed or greenhouse
- shredding leaves or woody garden waste
- using a leaf blower
- moving damp or mouldy bark, mulch or wood chips
- handling decaying plants
The concern is inhalation rather than simply touching an ordinary healthy plant. The amount released varies greatly with the material, moisture, temperature, weather, ventilation and how vigorously it is disturbed.
Compost is also one of the environmental settings in which azole-resistant Aspergillus fumigatus has been detected. This is another reason to reduce intense compost exposure, but it does not mean that every compost bag contains resistant fungus or that a single gardening session will cause infection.
Does Everyone With Aspergillosis Need the Same Precautions?
No. “Aspergillosis” includes several different illnesses, and people’s immune systems, lungs, treatments and gardening activities differ.
| Situation | How to think about gardening |
|---|---|
| Aspergillus allergy, asthma or ABPA | Dust, fungal particles and pollen may provoke airway symptoms. Concentrate on avoiding visible dust and high-spore tasks and make sure asthma treatment is well controlled. |
| CPA, bronchiectasis or another chronic lung condition | There is no precise exposure threshold known to be safe or harmful. Reducing concentrated exposure is sensible, while adapted lower-exposure gardening may remain valuable. |
| Severely weakened immune system | People who are neutropenic, receiving certain chemotherapy or transplant treatments, or otherwise at high risk of invasive aspergillosis may be advised to avoid gardening, soil, compost and dusty outdoor work. Follow the specialist team’s advice. |
| Taking corticosteroids or other immune-modifying treatment | Risk depends on the medicine, dose, duration and the rest of your health. Do not assume that every steroid inhaler creates the same risk as high-dose systemic immunosuppression; ask the clinical team if uncertain. |
If your immune status has recently changed—for example, following transplantation, chemotherapy, a major increase in systemic steroid treatment or a very low white-cell count—check whether your previous gardening routine remains appropriate.
Protective measures reduce exposure; they cannot make a high-exposure activity completely risk-free. The more vulnerable the person, the more important avoidance and delegation become.
Which Gardening Jobs Create the Most Exposure?
Consider asking someone else to do the following:
- turning or emptying a compost heap or bin
- opening, tipping or mixing bagged compost, manure, bark or mulch
- shredding or chipping garden waste
- handling heaps of dead leaves, grass clippings or rotting vegetation
- using a leaf blower or dry power sweeper
- mowing very dry grass, particularly if grass or pollen triggers symptoms
- cleaning a dusty or mouldy greenhouse, shed or plant pot store
- moving mouldy wood, hay, straw or stored bulbs
- pressure-washing or dry-brushing visibly mouldy surfaces
Distance matters. If someone else is doing one of these jobs, do not stand nearby. Stay upwind and allow airborne dust to settle before returning.
Dry and windy conditions make dust harder to control. Waiting for calmer weather or lightly dampening dry soil before someone works on it may reduce dust, although it will not remove fungal spores or make mouldy material safe.
Lower-Exposure Ways to Enjoy Gardening
Many activities involve little or no disturbance of compost or decaying matter. Depending on your mobility and respiratory health, possibilities include:
- watering established plants
- dead-heading healthy flowers before material begins to decay
- light pruning of healthy plants
- planning planting schemes or choosing plants
- harvesting fruit, vegetables or herbs from established plants
- using raised beds to reduce bending and effort
- working with someone else who handles soil and compost
- buying pre-planted containers rather than filling pots yourself
- photography, birdwatching or simply spending time in the garden
A “no-dig” approach may reduce repeated soil disturbance, although the compost or mulch used to establish it should be handled and spread by someone else.
Gardening can still be physically demanding. Pace activity, use lightweight or long-handled tools, sit for suitable tasks and take rests before breathlessness becomes severe. Pulmonary rehabilitation principles—gradual activity, pacing and breathing control—can be useful in the garden too.
Compost, Potting Mix, Mulch and Bark
Commercial bags are not sterile. Compost and related materials may contain fungi even when they look normal and carry no visible mould.
If possible, ask someone else to:
- open bags outdoors
- stand upwind while opening or pouring them
- avoid squeezing a sealed bag and forcing dusty air towards the face
- tip the material gently rather than from a height
- prepare pots before you enter the area
- close or cover unused material and store it outside living areas
Never open compost inside the home, greenhouse, conservatory, garage or shed. Enclosed spaces allow released particles to become concentrated and remain in the air.
Homemade compost heaps are particularly active biological environments. Adding kitchen or garden waste from a distance is less disturbing than turning, sieving or emptying the heap, but a severely immunocompromised person may be advised to avoid the area entirely.
Choosing and Using a Mask
A loose surgical mask, fabric face covering or single-strap “nuisance dust mask” is not designed to provide reliable protection from fine airborne dust and mould spores.
Use a certified filtering respirator marked to the appropriate standard. In the UK, disposable respirators should carry the relevant conformity marking and EN 149 classification.
- FFP2: may reduce inhalation during lower-level dusty tasks when it fits correctly.
- FFP3: provides a higher level of filtration and is advised by the Health and Safety Executive for high levels of mould spores.
The stated protection is only achieved when the respirator seals properly to the face.
- Follow the manufacturer’s fitting instructions.
- Check the seal every time it is worn.
- A beard or heavy stubble prevents a tight seal on most disposable respirators.
- Replace a disposable respirator if it becomes damp, damaged, dirty or difficult to breathe through.
- Do not touch the contaminated outside unnecessarily.
- Do not store a used disposable respirator in a dusty shed for repeated use.
A respirator can feel hot and may increase the sensation of breathing effort. If you have severe lung disease, discuss suitable respiratory protection with your clinical team. A reusable or powered option may sometimes be more appropriate, but it also requires correct selection, cleaning and maintenance.
A mask is the last line of protection, not the first. Avoiding or delegating a high-spore task is more reliable than using a mask to make the task appear completely safe.
Before, During and After Gardening
Before
- Check whether the planned job involves compost, decaying plants or visible dust.
- Choose a calm day and avoid the hottest part of the day if heat worsens breathlessness.
- Make sure prescribed inhalers and any agreed respiratory action plan are available.
- Cover cuts and broken skin with a waterproof dressing.
- Wear gloves, closed shoes and clothing that covers exposed skin for soil-related work.
- Use eye protection when pruning thorny plants, using powered tools or where debris may fly.
During
- Work upwind of any dust source.
- Avoid touching the face or adjusting the respirator with dirty gloves.
- Stop if you become unusually wheezy, tight-chested, dizzy or breathless.
- Do not push through severe symptoms simply to finish a job.
After
- Remove dusty shoes and outer clothing before entering the main living space.
- Wash hands and exposed skin thoroughly.
- Clean any scratches or puncture wounds promptly with soap and water.
- Shower and wash hair after a particularly dusty exposure if practical.
- Keep visibly dusty work clothing separate until it can be washed.
- Clean reusable protective equipment according to its instructions.
Plant thorns and sticks can injure the eye and, rarely, introduce fungi. Seek prompt assessment for eye pain, redness, sensitivity to light or blurred vision following a gardening injury.
Greenhouses, Sheds and Enclosed Spaces
A greenhouse or shed can accumulate dust, decaying leaves, old compost and mouldy wood. Because the air volume is small and ventilation may be poor, disturbing this material can create a more concentrated exposure than doing the same task outdoors.
- Ventilate the space fully before entering.
- Ask someone else to remove old compost, mouldy pots and decaying plants.
- Use wet-wiping rather than dry sweeping where appropriate.
- Do not use a leaf blower inside.
- Do not store open compost beside a frequently used chair or workspace.
- If the building smells strongly musty or has extensive visible mould, avoid entering until it has been dealt with.
What About Pollen and Asthma?
Fungal exposure is not the only gardening issue. Grass and other plant pollen can aggravate allergic rhinitis and asthma in susceptible people.
If pollen is one of your triggers:
- check the pollen forecast
- avoid mowing or being nearby while grass is cut
- garden outside peak pollen periods where possible
- choose plants less likely to release large quantities of wind-borne pollen
- change clothes and wash after high-pollen exposure
- keep asthma and allergy treatment under review
Pollen sensitivity and Aspergillus sensitivity are not the same thing, although a person may have both.
When Should I Seek Medical Advice?
A brief garden exposure does not automatically mean that you have developed a new fungal infection, and it is not usually possible to attribute ordinary day-to-day symptoms to a single exposure.
Follow your existing respiratory action plan and seek advice if symptoms are new, persistent or substantially worse than usual, particularly:
- increasing cough, wheeze or chest tightness that does not settle
- worsening breathlessness
- fever or feeling systemically unwell
- new or increased coughing of blood
- a sustained fall in oxygen levels from your usual range
Seek urgent medical help for severe breathing difficulty, blue or grey lips or skin, confusion, chest pain, fainting or significant haemoptysis. Follow the emergency advice appropriate to your country.
If you are severely immunocompromised and have had a major soil, compost or mould exposure, contact your specialist team for individual advice rather than starting or changing antifungal treatment yourself.
Finding a Sustainable Balance
Gardening offers genuine physical and emotional benefits. The aim of this guidance is not to remove those benefits unnecessarily.
For many people with aspergillosis, a workable balance is to continue lower-exposure activities while delegating compost handling, leaf blowing, shredding, dry sweeping and other jobs that generate concentrated dust. Correctly fitted respiratory protection adds another layer when exposure cannot be avoided.
People at high risk of invasive aspergillosis need more cautious, personalised advice and may need to avoid soil and compost work during vulnerable periods.
Keep the garden where possible; change the way the riskiest jobs are done.
Further Reading and References
- NHS: Aspergillosis
- US Centers for Disease Control and Prevention: Reducing risk for aspergillosis
- Health and Safety Executive: Disposable dust masks, fit and protection levels
- Shelton JMG and colleagues: Citizen-science surveillance of triazole-resistant Aspergillus fumigatus in UK residential garden soils
- Poole CJM and colleagues: Allergic bronchopulmonary aspergillosis in garden-waste compost workers
- US Centers for Disease Control and Prevention: Fungal eye infections and plant-material injuries
- Royal Horticultural Society: Gardening for health and wellbeing
Last reviewed: August 2026.
Living with Aspergillosis: Understanding the Brain–Lung Connection

Why emotions, stress, sleep, confidence and the nervous system all influence how we experience chronic lung disease
Aspergillosis Living Knowledge Hub | Built with patients | Living document
This is a Living Knowledge Hub
Unlike a traditional article, this Knowledge Hub is designed to evolve.
As new scientific research becomes available, and as people living with aspergillosis ask new questions, we will continue to expand and improve this resource.
The current version already contains evidence-based information that has been reviewed before publication, but it is only the beginning.
This approach allows us to share useful information now, rather than waiting until every section is complete, while continuing to improve the resource over time.
- Current version: 0.2
- Last updated: August 2026
- Status: Living Knowledge Hub
- Reading time: approximately 28 minutes
- Who is this for? People living with aspergillosis, families, carers and healthcare professionals
- Review policy: This Knowledge Hub is reviewed whenever important new evidence becomes available and at least annually to ensure it remains accurate and up to date.
Planned additions
- Living with uncertainty and recognising meaningful change
- More detail on pulmonary rehabilitation and rebuilding confidence
- Further patient experiences and questions
- Additional illustrations and diagrams
Contents
- Before you begin: you are not imagining it
- Why we wrote this guide
- Why does my breathing feel worse when my scan has not changed?
- Why does the brain matter if my lungs are the problem?
- Can emotions really change my breathing?
- How do the brain, stress system and immune system communicate?
- Can stress make aspergillosis worse?
- Why do sleep and breathing affect each other?
- Where do medicines fit into the brain–lung connection?
- When coughing becomes socially difficult
- What if I also have bronchiectasis, asthma or sinusitis?
- What can help?
- What’s new?
- Help us improve this Knowledge Hub
Before you begin…
If you have arrived here because someone suggested that stress or anxiety might be affecting your breathing, this page is for you.
If you have arrived here because you are wondering why some days are so much harder than others, this page is for you.
If you have ever worried that family members, friends or even healthcare professionals thought your symptoms were “all in your head”, this page is for you too.
And if you are a family member or healthcare professional trying to understand what it is really like to live with aspergillosis, we hope this guide helps explain an aspect of chronic lung disease that is rarely discussed in detail.
The most important message comes first.
Your illness is real.
Your symptoms are real.
Modern respiratory medicine recognises that the brain, lungs, nervous system and immune system constantly work together. Understanding that relationship does not make your illness any less real. It helps explain why living with chronic lung disease can sometimes be so challenging.
Why we wrote this guide
Over many years at the National Aspergillosis Centre, we have listened to many people living with aspergillosis.
Again and again, we hear similar questions.
“Why do I feel much worse today when my scan hasn’t changed?”
“Why does poor sleep affect my breathing so much?”
“Can stress make my symptoms worse?”
“If my emotions affect my breathing, does that mean my illness isn’t real?”
These are important questions. Unfortunately, they can be difficult to answer fully during a busy clinic appointment.
This guide has been written to provide the explanation many people tell us they never had.
It brings together modern respiratory medicine, neuroscience, immunology, pulmonary rehabilitation and the lived experience of people with aspergillosis.
Our aim is not simply to explain the science. Our aim is to help you understand your own experience.
A false choice
Many people living with chronic illness feel they have been offered two very different explanations for their symptoms.
Either the symptoms are caused by the lungs, or the symptoms are caused by anxiety.
Modern medicine increasingly recognises that this is a false choice.
The lungs are real. The brain is real. The nervous system is real. The immune system is real. Hormones are real.
Every one of these systems communicates continuously with the others. When we understand that partnership, many experiences that once seemed confusing begin to make sense.
More than just the lungs
Most of us think breathing happens entirely inside the lungs. In reality, every breath depends on an extraordinary partnership between many different parts of the body.
| Body system | Its role in breathing |
|---|---|
| The lungs | Exchange oxygen and carbon dioxide. |
| The brain | Interprets breathing signals and decides how much air the body needs. |
| The nervous system | Adjusts breathing, heart rate and muscle activity. |
| The breathing muscles | Power every breath you take. |
| The immune system | Responds to infection and inflammation in the lungs. |
| Your previous experiences | Help the brain judge whether breathing feels safe or threatening. |
Scientists often describe this constant communication as the brain–lung axis.
Understanding how this partnership works has transformed the way respiratory specialists think about chronic breathlessness.
What you will learn
By the end of this guide you will understand:
- why scans and lung function tests do not always match how you feel
- why frightening experiences can change the way breathing feels
- why sleep, fatigue and emotions influence symptoms
- what scientists know about stress and the immune system
- why pulmonary rehabilitation works
- how confidence can be rebuilt after serious illness
- what is known, and what is still uncertain, about these important questions.
If you remember only one thing from this opening section, remember this:
Your illness is real. Your symptoms are real. The science that explains the connection between the brain and lungs is real too.
Why Does My Breathing Feel Worse When My Scan Hasn’t Changed?
This is probably one of the most common questions asked by people living with chronic lung disease.
“My doctor says my CT scan looks stable, so why do I feel so much worse?”
It is an excellent question. It is also one that causes enormous frustration.
Many people begin wondering whether they are imagining their symptoms or whether something has been missed.
Fortunately, modern respiratory medicine has a much better explanation.
The first thing to understand
A CT scan is an extraordinarily useful investigation. It allows doctors to see inflammation, cavities, bronchiectasis, scarring and many other important changes inside the lungs.
But a scan has one important limitation.
It shows what your lungs look like.
It cannot show what breathing feels like.
Those are two different things.
Structure versus function
A useful way to think about this is to separate structure from function.
| Structure | Function and lived experience |
|---|---|
| CT scans | Breathing comfort and effort |
| X-rays | Exercise tolerance |
| Blood tests | Energy and fatigue |
| Lung function tests | Quality of life and confidence |
Your medical team needs both kinds of information. One does not replace the other.
Breathlessness is an experience
The American Thoracic Society defines breathlessness, also called dyspnoea, as:
“A subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity.”
That definition is important. It tells us that breathlessness is something that is experienced.
The lungs send information. The brain turns that information into the experience of breathing.
An orchestra, not a solo instrument
Imagine listening to an orchestra. You do not hear only the violins. You hear the combined sound of strings, woodwind, brass and percussion.
Breathing works in much the same way. What you experience is produced by many different systems working together.
| System | Contribution |
|---|---|
| Lungs | Move oxygen and carbon dioxide. |
| Heart | Delivers oxygen. |
| Breathing muscles | Generate each breath. |
| Brain | Interprets signals. |
| Nervous system | Adjusts breathing. |
| Sleep | Influences fatigue and resilience. |
| Confidence | Changes how safe breathing feels. |
| Previous experiences | Influence future breathing responses. |
No single instrument produces the whole performance.
What your scan cannot see
Your CT scan cannot show:
- how well you slept
- whether your breathing muscles are tired
- whether you recently recovered from a viral infection
- whether you feel anxious about another haemoptysis
- whether today’s humidity is making your chest feel tight
- whether your body is still recovering from yesterday’s activity
- how much mental effort breathing requires today.
All of these may influence how breathing feels. None of them mean your illness is imaginary.
Research Spotlight
Why the modern definition of breathlessness matters
Older medical thinking often treated breathlessness as a simple consequence of lung damage.
Research over recent decades has shown that the experience of breathlessness depends upon interactions between the lungs, brain, nervous system and many other factors.
This is why modern respiratory medicine increasingly measures quality of life alongside scans and lung function tests.
Why this matters: it validates what patients have always known: how they feel cannot always be predicted by test results alone.
Why this matters if you have aspergillosis
If your scan has not changed but your breathing feels worse, this does not automatically mean:
- the disease has suddenly progressed
- the scan is wrong
- your symptoms are “all in your head”.
It means breathing is influenced by many different parts of the body working together.
Understanding those interactions is one of the biggest advances in modern respiratory medicine.
Why Does the Brain Matter If My Lungs Are the Problem?
This question worries many people.
“If my doctor starts talking about my brain, are they saying my illness isn’t real?”
The answer is simple. No.
Talking about the brain is not changing the diagnosis. It is explaining how breathing works.
Your lungs cannot create the sensation of breathlessness on their own, just as your ears cannot create music on their own, or your eyes cannot create vision on their own.
Every one of these experiences depends on the brain interpreting information coming from the body. Breathing is no different.
Your brain is your body’s prediction machine
Most of us imagine the brain as a computer that simply receives information. Modern neuroscience paints a much more interesting picture.
The brain is constantly trying to predict what is about to happen.
Every second it asks questions such as:
- Am I safe?
- Am I getting enough oxygen?
- Should I breathe faster?
- How hard are my breathing muscles working?
- Does this feel familiar?
It compares what it expects to happen with what is actually happening.
If everything matches, breathing usually fades into the background. If something unexpected happens, breathing suddenly becomes the centre of attention.
This is one reason healthy people rarely notice their breathing, while people living with chronic lung disease may think about it many times each day.
The smoke alarm inside your brain
A smoke alarm has one job: to detect danger. It would rather ring unnecessarily than miss a real fire.
Your brain works in much the same way.
If you have experienced:
- a severe asthma attack
- haemoptysis
- being unable to catch your breath
- an emergency admission to hospital
- months of unexplained symptoms before diagnosis
your brain learns something very important.
“Breathing can sometimes become dangerous.”
Once that lesson has been learned, your brain naturally pays much closer attention to breathing than it did before.
This is not a fault. It is exactly what evolution intended. Your brain is trying to protect you.
Patient Perspective
“After coughing up blood I became frightened every time I coughed.
I knew the bleeding had stopped, but every cough made me wonder whether it was happening again.
Learning that my brain was trying to protect me, not trick me, changed the way I understood my recovery.”
The Brain–Lung Axis
Scientists describe the close communication between the brain and lungs as the brain–lung axis.
This communication works in both directions.
| The lungs tell the brain… | The brain tells the lungs… |
|---|---|
| How much oxygen is available. | How fast to breathe. |
| How much carbon dioxide is present. | How deeply to breathe. |
| Whether the airways are irritated. | When to cough. |
| How hard the breathing muscles are working. | How to respond to exercise. |
Every breath is the result of this continuous conversation.

Why this matters if you have aspergillosis
If you understand that breathing is created by a partnership between the lungs and brain, several confusing experiences suddenly make much more sense.
- Why one day can feel much harder than another.
- Why sleep affects breathing.
- Why fatigue affects breathing.
- Why confidence affects breathing.
- Why pulmonary rehabilitation improves symptoms even when scans remain unchanged.
- Why frightening respiratory events can continue to affect confidence long after the lungs have recovered.
None of these observations suggest your illness is psychological.
They demonstrate how remarkably sophisticated the breathing system really is.
Research Spotlight
Brain imaging studies have shown that breathlessness activates areas of the brain involved in attention, emotion and decision-making, as well as areas involved in sensory processing.
This reinforces an important message:
Breathlessness is not simply a signal from the lungs. It is a whole-body experience.
Can Emotions Really Change My Breathing?
Many people living with aspergillosis are reluctant to ask this question.
Some worry that even mentioning stress or emotions will mean their symptoms are no longer taken seriously. Others have experienced exactly that in the past.
Modern respiratory medicine takes a very different view.
It recognises two equally important facts.
- Your lung disease is real.
- Your emotional state can influence how that disease is experienced.
These statements are not contradictory. They describe how the human body normally works.
Every emotion has a physical effect
Think about the last time you were startled. Before you had time to think, your body had already responded.
- Your heart rate increased.
- Your breathing became faster.
- Your muscles tightened.
- Your mouth became dry.
- Your attention narrowed onto the potential danger.
You did not choose any of those reactions. They happened automatically.
This is because emotions are not separate from the body. They are produced by the body and immediately affect the body’s physiology.
Breathing is especially sensitive
Unlike many other organs, the breathing system has to respond continuously to both physical demands and emotional demands.
| Situation | What happens? |
|---|---|
| Walking upstairs | Your breathing increases because your muscles need more oxygen. |
| Receiving frightening news | Your breathing may also increase, even though your muscles are resting. |
| Laughing | Your breathing pattern changes completely. |
| Crying | Your breathing becomes irregular and deeper. |
| Feeling calm and relaxed | Your breathing usually slows and becomes more efficient. |
These changes happen in everyone.
People with chronic lung disease often notice them more because their breathing system is already working harder.
Why frightening experiences matter
Imagine two people climbing exactly the same flight of stairs.
One has never experienced serious breathing problems. The other has previously been admitted to hospital with severe breathlessness.
Their lungs may be working equally hard. But their brains interpret those signals differently.
The first person thinks:
“I’m out of breath because I climbed the stairs.”
The second person may immediately wonder:
“Is something going wrong again?”
Neither response is irrational. They reflect different life experiences.
This is one reason why previous severe respiratory events can continue to influence confidence long after recovery.
Patient Perspective
“I realised I wasn’t frightened of exercise.
I was frightened of becoming breathless because, in the past, breathlessness had meant I was seriously ill.”
The vicious circle of fear
Fear itself does not damage the lungs. However, fear can unintentionally make breathing feel more difficult.
Breathlessness
↓
Concern
↓
Breathing becomes faster
↓
Chest muscles tighten
↓
Breathing feels harder
↓
More concern
This is not imaginary. Every stage involves genuine physical changes.
The encouraging news is that this cycle can also be interrupted.
Understanding
↓
Greater confidence
↓
Calmer breathing
↓
More efficient breathing
↓
Activity feels easier
↓
Confidence grows
This does not remove aspergillosis. It changes how effectively the whole breathing system works together.
Research Spotlight
Why pulmonary rehabilitation improves confidence
Research consistently shows that pulmonary rehabilitation improves quality of life, exercise capacity and confidence, even when lung function changes only modestly.
Patients often describe feeling more in control of their breathing.
This improvement reflects better physical conditioning, improved breathing efficiency, increased confidence and a better understanding of symptoms.
These benefits are recognised internationally and form an important part of managing many chronic respiratory diseases.
Why this matters if you have aspergillosis
You are not expected to ignore your emotions.
You are not expected to “stay positive” all the time.
You are not expected to pretend your illness is less serious than it is.
Instead, understanding how emotions influence breathing gives you another tool.
It helps explain why:
- some days feel harder than others
- confidence matters
- breathing techniques can help
- pulmonary rehabilitation works
- being listened to is part of good medical care
Knowledge does not remove the disease.
But it can remove unnecessary fear and replace it with understanding.
Emotions do not make aspergillosis imaginary.
They are one of the many biological systems that influence how living with aspergillosis feels from day to day.
How Do the Brain, Stress System and Immune System Communicate?
The brain and immune system are not separate departments. They exchange information continuously through nerves, hormones and chemical messengers.
The scientific field that studies these connections is called psychoneuroimmunology:
- psycho refers to thoughts, emotions and behaviour
- neuro refers to the brain and nervous system
- immunology refers to the immune system
The name may sound as though it is about psychology alone. It is not. It describes measurable biological communication between the nervous, hormonal and immune systems.
What happens during a stress response?
When the brain detects a possible threat, it activates two closely connected systems.
| System | What it does |
|---|---|
| The sympathetic nervous system | Acts rapidly. Adrenaline and related signals can increase heart rate, blood pressure, alertness and breathing. |
| The hypothalamic–pituitary–adrenal axis | Produces a slower hormonal response involving cortisol, which helps regulate energy use, inflammation and immune activity. |
This response is useful when danger is brief. It prepares the body to act and then, normally, settles again.
Long-lasting illness can be different. Symptoms, uncertainty, poor sleep, repeated hospital visits and frightening events may keep the body’s alarm systems more active than usual. Researchers call the accumulated strain of repeated adaptation allostatic load.
Does stress simply weaken the immune system?
No. That common phrase is too simple.
Stress signals can increase some immune responses and reduce or redirect others. The effect depends on how intense and prolonged the stress is, what else is happening in the body, which part of the immune system is measured and the individual person.
Human studies have shown that sustained psychological stress can be associated with greater susceptibility to some viral respiratory infections. Sleep disruption can also alter inflammatory and immune signalling. However, these findings cannot simply be transferred to every disease or every patient.
The essential distinction
Stress does not create Aspergillus, and there is no good evidence that stress alone causes aspergillosis.
Aspergillosis develops through an interaction between fungal exposure, the lungs, the immune system and individual susceptibility. Stress and sleep may influence parts of that wider system, but they are not substitutes for diagnosis, antifungal treatment, asthma treatment or specialist care.
Why this matters: the brain–immune connection is real, but it must never be used to blame someone for becoming ill or for failing to recover.
Can Stress Make Aspergillosis Worse?
This question needs a careful answer.
There is currently not enough direct research to say that psychological stress makes the fungus grow, causes aspergillosis to progress or produces a relapse. We should not claim more than the evidence shows.
Stress can nevertheless affect the experience and management of illness through several genuine biological and practical routes:
- breathing may become faster or less regular
- heart rate and blood pressure may rise temporarily
- chest and shoulder muscles may tighten
- sleep may become more fragmented
- fatigue and pain may become harder to tolerate
- attention may become fixed on breathing or coughing
- activity may be avoided through fear of breathlessness
- complex treatments and airway-clearance routines may become harder to manage
These effects can make a difficult day feel substantially worse even when the underlying lung disease has not suddenly changed.
The reverse is also important. Worsening respiratory symptoms can create stress. The relationship therefore runs in both directions:
Symptoms can increase stress, and stress can amplify the experience and consequences of symptoms.
Do not assume that a change is “only stress”
A new or persistent deterioration still deserves appropriate medical assessment. Stress may be one influence, but it must not be used to dismiss infection, an asthma flare, mucus plugging, medicine side effects, low oxygen levels or progression of lung disease.
Why Do Sleep and Breathing Affect Each Other?
One reader told us that understanding the importance of sleep was especially helpful. Sleep deserves its own section because the relationship again works in both directions.
Lung symptoms can disturb sleep
Cough, sputum, wheeze, breathlessness, reflux, pain, medicines and worry can all interrupt sleep. People may also wake to clear mucus, use an inhaler or change position.
Research in adults with stable bronchiectasis found sleep disturbance to be common and associated with poorer health-related quality of life. That does not prove that bronchiectasis is the only cause of poor sleep, but it confirms that the problem deserves attention rather than being accepted as an inevitable inconvenience.
Poor sleep can make the next day harder
After disrupted sleep:
- physical and mental energy are reduced
- concentration and memory may be poorer
- the brain may have less capacity to filter or tolerate uncomfortable sensations
- breathlessness and coughing may feel more intrusive
- emotional resilience may be lower
- motivation for exercise, airway clearance and treatment routines may fall
This can produce another self-reinforcing loop:
Night-time symptoms → broken sleep → fatigue and greater symptom burden → reduced activity or coping capacity → a more difficult night.
Could it be a sleep disorder?
Not every sleep problem is caused by aspergillosis. Loud snoring, witnessed pauses in breathing, gasping or choking during sleep, morning headaches and marked daytime sleepiness can be features of obstructive sleep apnoea. These symptoms should be discussed with a GP or respiratory team because sleep apnoea can be assessed and treated.
Sleep is not a cure for aspergillosis. Improving a treatable sleep problem may, however, improve energy, concentration, mood and the ability to manage respiratory illness.
Where Do Medicines Fit into the Brain–Lung Connection?
A reader asked about “the effect of pharmaceuticals within the loop”. This is an important question because medicines can influence several parts of the system at once.
| Medicine or treatment | How it may affect the wider system |
|---|---|
| Antifungal treatment | Targets the fungal infection or fungal burden. Effective treatment may reduce inflammation and respiratory symptoms, while side effects or interactions can affect energy, sleep or general wellbeing. |
| Inhaled bronchodilators | Can make breathing easier by opening the airways. Some people temporarily notice shaking, palpitations or a faster heartbeat, which can themselves feel alarming. |
| Corticosteroids | Can reduce allergic and airway inflammation, particularly in conditions such as ABPA and asthma. Systemic steroids can also affect sleep, mood, appetite, blood pressure, blood glucose and adrenal function. |
| Mucus and airway-clearance treatments | May loosen or mobilise secretions. This can temporarily provoke more coughing even when the treatment is doing something useful. |
| Sedating medicines, alcohol and some pain medicines | May alter alertness, sleep quality or breathing. Their effects vary and can be particularly important when several medicines are taken together. |
Azole antifungals can interact with many other medicines, sometimes increasing or decreasing drug levels. A medication review by a pharmacist or specialist team is therefore part of good aspergillosis care.
Do not stop or change prescribed treatment because of this section. If a medicine appears to affect sleep, mood, heart rate, blood pressure or breathing, discuss the timing, dose, interactions and possible alternatives with the prescribing team or a pharmacist.
What If I Also Have Bronchiectasis, Asthma or Sinusitis?
Another reader asked us to recognise the respiratory conditions that often exist alongside aspergillosis. The brain does not receive neatly labelled messages from one diagnosis at a time. It receives a combined stream of information from the whole respiratory system.
| Condition or problem | Signals it may add |
|---|---|
| Aspergillosis | Inflammation, infection, tissue damage, cough, fatigue and uncertainty about changing symptoms. |
| Bronchiectasis | Mucus retention, airway clearance, recurrent infections and unpredictable coughing. |
| Asthma | Variable airway narrowing, wheeze, chest tightness and sometimes sudden episodes of breathlessness. |
| Chronic sinusitis or nasal disease | Nasal obstruction, post-nasal drainage, facial discomfort, disturbed sleep and upper-airway irritation. |
| Reflux, pain or deconditioning | Additional cough triggers, restricted movement and increased effort during activity. |
This helps explain why treating one part of the problem may bring a real improvement without making every symptom disappear. It also explains why coordinated care and a clear treatment plan matter when several diagnoses overlap.
What Can Help?
Understanding the brain–lung connection should lead to more options, not fewer. It adds supportive treatments to appropriate medical care; it does not replace that care.
1. Learn your own patterns
A short symptom diary can reveal links between sleep, activity, medicines, airway clearance, stressful events and breathing. Look for patterns rather than blaming yourself for individual difficult days.
2. Treat the lungs properly
Antifungals, asthma treatment, infection management, airway clearance and monitoring remain central where clinically indicated. A brain–lung explanation must never become a reason to undertreat physical disease.
3. Rebuild confidence gradually
Pulmonary rehabilitation and appropriately paced activity can help the brain relearn that breathlessness during safe activity does not always signal immediate danger. Progress may be slow and uneven.
4. Use breathing control appropriately
Techniques taught by a respiratory physiotherapist can help some people recover from an episode of difficult breathing or manage the urge to breathe rapidly. Airway clearance and breathing control have different purposes, so personalised instruction is valuable.
5. Investigate persistent sleep problems
Do not assume that severe daytime sleepiness, repeated waking, loud snoring or night-time breathing difficulty is simply part of aspergillosis. Discuss it with a healthcare professional.
6. Review medicines
Ask whether the timing, dose, side effects or interactions of medicines could be affecting sleep, mood, energy, heart rate or breathing. This is particularly important when azole antifungals, steroids or several long-term medicines are used together.
7. Create a plan for genuine deterioration
Knowing what is normal for you—and when to seek help—can reduce uncertainty. Ask your clinical team what changes should trigger routine advice, urgent assessment or emergency help.
Seek urgent medical help
Do not try to manage severe or rapidly worsening breathlessness as anxiety alone. Seek urgent help for symptoms such as severe difficulty breathing, blue or grey lips or skin, confusion, chest pain, fainting, a major fall in oxygen levels, or significant coughing of blood. Follow the emergency advice appropriate to your country.
What the evidence can—and cannot—tell us
| Evidence position | What we can reasonably say |
|---|---|
| Well established | The brain constructs the experience of breathlessness from signals coming from the lungs and the rest of the body. Emotions, attention, previous experiences and physical physiology all contribute. |
| Supported across chronic respiratory disease | Poor sleep, anxiety, disease-specific fears and social restriction are common and can worsen quality of life. Pulmonary rehabilitation can improve exercise capacity, confidence and symptom management. |
| Biologically established but individually complex | The nervous, hormonal and immune systems communicate. Stress and sleep can alter immune and inflammatory signals, but the direction and clinical importance vary. |
| Not yet established | That psychological stress directly causes aspergillosis, makes Aspergillus grow or independently causes a relapse. |
If you remember only one message from this update, remember this:
Good care does not ask whether symptoms come from the lungs or the brain. It asks how the lungs, brain, nervous system, immune system, sleep, medicines and lived experience are interacting—and what can safely be improved.
What’s New?
This Knowledge Hub is updated as new evidence becomes available and in response to questions from readers.
Version 0.2 – August 2026
- Added the immune system and psychoneuroimmunology.
- Explained stress hormones, inflammation and the limits of current evidence.
- Added a detailed section on sleep and breathing.
- Explained how medicines can affect different parts of the brain–lung system.
- Added the patient-identified cycle linking social activity, mucus, coughing and anxiety.
- Recognised the combined effects of aspergillosis, bronchiectasis, asthma and chronic sinusitis.
- Added practical steps and clearer safety advice.
Version 0.1 – July 2026
- Initial publication.
- Introduced the brain–lung connection.
- Explained why breathlessness is more than lung function alone.
- Explored how previous experiences and emotions can influence breathing.
Next planned update
- Living with uncertainty and recognising meaningful change.
- More detail on pulmonary rehabilitation and rebuilding confidence.
- Further patient experiences and questions.
Help Shape Future Editions
Every month we review this Knowledge Hub.
Some improvements come from newly published scientific research.
Others come directly from the questions and experiences shared by people living with aspergillosis, their families and healthcare professionals.
Many of the most valuable pages on aspergillosis.org have started with a single patient question.
If there was something you expected to find but didn’t…
If something wasn’t explained clearly…
If your own experience has been different…
Or if there is a question you think every patient should have answered…
Please tell us.
Your feedback will help shape future editions of this Knowledge Hub and may inspire entirely new patient resources.
📝 Share your feedback (2–3 minutes)
Thank you for helping us build one of the world’s most comprehensive patient education resources on aspergillosis.
This Knowledge Hub has evolved thanks to our readers
Future updates will be listed here so you can see how this resource has grown over time.
| Version | What changed |
|---|---|
| 0.1 | Initial publication introducing the brain–lung connection, explaining why breathlessness is more than lung function, and describing how previous experiences and emotions can influence breathing. |
| 0.2 | Added immune and hormonal communication, stress and inflammation, sleep, medicines, overlapping respiratory conditions, patient-informed social coughing experiences, practical actions and safety advice. |
| 0.3 | Planned: living with uncertainty, pulmonary rehabilitation and further patient-informed additions. |
| 1.0 | First complete edition. |
Further reading and references
- American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea
- American Thoracic Society PDF: Mechanisms, Assessment, and Management of Dyspnea
- American Thoracic Society patient information: Pulmonary Rehabilitation
- British Thoracic Society: Pulmonary Rehabilitation resources
- Global Initiative for Asthma (GINA)
- Global Initiative for Chronic Obstructive Lung Disease (GOLD)
- PubMed search: brain imaging and dyspnoea reviews
- PubMed search: quality of life in chronic pulmonary aspergillosis
- Aspergillosis Patients & Carers website
- Cohen S, Tyrrell DAJ, Smith AP. Psychological Stress and Susceptibility to the Common Cold. New England Journal of Medicine. 1991.
- McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Annals of the New York Academy of Sciences. 1998.
- Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annual Review of Psychology. 2015.
- Gao YH et al. Sleep disturbances and health-related quality of life in adults with steady-state bronchiectasis. PLoS ONE. 2014.
- Sigurgeirsdottir J et al. COPD patients’ experiences, self-reported needs, and needs-driven strategies to cope with self-management. International Journal of Chronic Obstructive Pulmonary Disease. 2019.
- NHS: Sleep apnoea—symptoms, assessment and treatment.
- NHS: Side effects of prednisolone tablets and liquid.
Suggested citation: National Aspergillosis Centre. Living with Aspergillosis: Understanding the Brain–Lung Connection. Aspergillosis.org. Version 0.2. August 2026.
Could One Biologic Treat Nasal Polyps, Asthma and ABPA?

People living with ABPA sometimes also experience severe asthma, chronic sinus inflammation and nasal polyps that return after surgery. These may appear to be separate problems, but they can be driven partly by the same type of immune response.
This has created an important new treatment possibility. Instead of repeatedly treating the nose and lungs as unrelated problems, a biological medicine may sometimes reduce inflammation in both.
Dupilumab (brand name Dupixent) is one such biologic. It is an established treatment for selected people with severe chronic rhinosinusitis with nasal polyps and for some forms of asthma. Early clinical-trial evidence also suggests that it may benefit some people with asthma and allergic bronchopulmonary aspergillosis (ABPA), although it is not currently licensed specifically as an ABPA treatment.
Key points
- Dupilumab can shrink severe nasal polyps, improve nasal blockage and help some people regain their sense of smell.
- It can also improve suitable forms of asthma because the nose and lungs may share the same type of inflammation.
- Promising results have been reported from a randomised phase 2 trial in people with both asthma and ABPA.
- Dupilumab does not kill Aspergillus and is not a replacement for antifungal treatment when antifungals are needed.
- The most suitable biologic should ideally be chosen jointly by ENT, respiratory and severe-asthma specialists.
Why do nasal polyps keep returning?
Nasal polyps are soft, non-cancerous swellings that develop from chronically inflamed tissue inside the nose and sinuses. They can cause:
- persistent nasal blockage;
- loss or reduction of smell;
- an apparent loss of taste, because much of what we experience as flavour depends on smell;
- nasal discharge or post-nasal drip;
- facial pressure; and
- poor sleep and fatigue.
Functional endoscopic sinus surgery (FESS) can remove polyps, improve drainage and allow nasal treatments to reach the sinuses more effectively. However, surgery removes the obstructing tissue; it does not necessarily switch off the inflammation that caused it. In people with strong ongoing inflammation, polyps may therefore grow back—occasionally quite quickly.
A nasal endoscopy shows what is visible inside the nose, while a CT scan helps the ENT team assess the full extent of inflammation and blockage throughout the sinuses. The results help determine whether further surgery, medical treatment or a biologic is the most appropriate next step.
The link between the nose, asthma and ABPA
The upper and lower airways form one connected system. Many people with nasal polyps also have asthma, and both conditions are frequently associated with type 2 inflammation.
In this pattern of inflammation, immune signals including interleukin-4 (IL-4), interleukin-13 (IL-13), interleukin-5, immunoglobulin E (IgE) and eosinophils can contribute to swelling, mucus production and airway symptoms.
ABPA is more complicated because it involves an exaggerated immune response to Aspergillus, usually in a person with asthma, bronchiectasis or another susceptible airway condition. Nevertheless, type 2 inflammation is also an important part of ABPA. This overlap creates the possibility that a treatment targeting one pathway could benefit more than one part of the airway.
However, having both ABPA and nasal polyps does not automatically mean that Aspergillus is growing in the sinuses. Allergic fungal rhinosinusitis is a separate diagnosis requiring its own ENT assessment. You can read more in our guide to Aspergillus and allergic fungal disease in the sinuses.
How does dupilumab work?
Dupilumab is a monoclonal antibody—a highly targeted biological medicine. It attaches to part of the receptor used by both IL-4 and IL-13, reducing signals that drive type 2 inflammation.
It is not a general immune suppressant in the way that oral corticosteroids are, and it is not an antifungal drug. It targets a particular inflammatory pathway rather than killing Aspergillus.
For adults with severe nasal polyps, dupilumab is normally given by injection under the skin, commonly every two weeks. After training, many people can administer it themselves. It is generally used as ongoing maintenance treatment rather than as a short, fixed course, and prescribed nasal corticosteroid treatment is usually continued.
How much can it help nasal polyps?
In the large SINUS-24 and SINUS-52 clinical trials, adding dupilumab to standard nasal corticosteroid treatment reduced polyp size and nasal congestion, improved sinus-related quality of life and improved sense of smell. Across the pooled trial population, it also substantially reduced the need for systemic corticosteroids and further sinus surgery.
Some people notice an improvement in congestion relatively early, but regaining smell and achieving the full benefit may take longer. Not everyone responds, and a completely normal sense of smell cannot be guaranteed—particularly if olfactory nerves have been affected by longstanding disease or another cause.
What do we know about dupilumab in ABPA?
Biologics are already used in selected people with severe asthma and treatment-dependent ABPA, particularly when repeated courses of oral corticosteroids are needed. The 2024 international ISHAM-ABPA guidelines recognised biologics as an option for treatment-dependent disease, but they are not recommended as routine first-line treatment for a new acute ABPA episode.
The phase 2 LIBERTY ABPA AIRED trial was the first randomised placebo-controlled study of dupilumab in adults with asthma and ABPA. It enrolled 62 participants. Results presented at respiratory conferences in 2025 reported improvements in lung function and quality of life, together with fewer severe respiratory exacerbations and reduced corticosteroid use.
These findings are encouraging and provide stronger evidence than earlier case reports. However, the study was small and the findings have so far principally been reported in conference abstracts. Dupilumab is therefore best described as a promising emerging treatment for ABPA, not a proven cure or a licensed ABPA treatment.
It is also important to distinguish control of inflammation from control of fungal growth. Dupilumab may calm the allergic response, but it does not remove Aspergillus from the airway and will not replace antifungal medication when a specialist believes antifungal treatment is required.
Who can receive dupilumab for nasal polyps on the NHS?
In February 2026, NICE recommended dupilumab as an add-on to intranasal corticosteroids for a defined group of adults in England with severe chronic rhinosinusitis with nasal polyps.
The NICE criteria include:
- disease that remains inadequately controlled by systemic corticosteroids or sinus surgery;
- at least one previous sinus operation; and
- a score of at least 50 on the 22-item Sinonasal Outcome Test (SNOT-22).
SNOT-22 is a questionnaire measuring the effect of sinus symptoms on daily life, including blockage, smell and taste, sleep, fatigue, concentration and emotional wellbeing. A polyp “stage” seen during nasal endoscopy is useful clinical information, but it is not by itself the same as meeting the full NHS eligibility criteria.
Access arrangements can differ outside England and may change over time. A specialist team must assess eligibility and whether dupilumab is the best option for the individual.
Choosing a biologic when several conditions overlap
Dupilumab is not the only biologic used in airway disease. Other medicines target IgE, IL-5, the IL-5 receptor or TSLP. The best choice depends on the complete clinical picture, which may include:
- the severity and recurrence of nasal polyps;
- asthma control and the number of exacerbations;
- ABPA activity and previous treatments;
- blood eosinophil levels and fractional exhaled nitric oxide (FeNO);
- total IgE and allergen-specific IgE;
- the need for repeated or maintenance oral steroids;
- other conditions such as eczema; and
- previous response or side effects with another biologic.
For someone with severe recurrent nasal polyps, asthma and ABPA, dupilumab may be particularly attractive because it has the potential to address inflammation in both the upper and lower airways. However, another biologic may be a better match for some patients. Ideally, ENT and respiratory or severe-asthma teams should coordinate the decision rather than considering each condition in isolation.
For a broader explanation, see how NHS specialists choose biologics for ABPA and severe asthma.
What are the possible side effects?
Dupilumab is generally well tolerated, but possible adverse effects include:
- redness, swelling, itching or discomfort at the injection site;
- eye irritation or conjunctivitis;
- joint pain;
- cold sores; and
- a temporary rise in blood eosinophils.
Serious allergic reactions are rare. New or worsening eye symptoms, marked joint symptoms, a rash, breathing deterioration or other concerning symptoms should be reported to the treating team. Patients should not stop asthma inhalers, nasal treatment, corticosteroids or antifungals when starting a biologic unless their specialist provides a supervised plan.
A note about IgE and IgG
Patients understandably sometimes refer to having a “high IgG” or a “high allergy count”, but several different antibody tests may be used in ABPA.
- Total IgE reflects overall allergic activity and is commonly followed over time in ABPA.
- Aspergillus fumigatus-specific IgE demonstrates allergic sensitisation to the fungus.
- Aspergillus-specific IgG can provide evidence of immune exposure and forms part of the wider diagnostic picture, but it is not interchangeable with total IgE.
Biologic treatment can alter inflammatory markers, so blood results must be interpreted alongside symptoms, lung function and imaging rather than in isolation.
Questions to ask your specialist team
- Do my symptoms and SNOT-22 score meet the criteria for biologic treatment?
- Is my loss of smell likely to be caused entirely by polyps, or should other causes be considered?
- Could one biologic reasonably treat both my nasal disease and asthma?
- How active is my ABPA at present, and what benefit might the biologic provide?
- Will my ENT and respiratory or severe-asthma teams discuss the choice together?
- How and when will my response be assessed?
- Which nasal sprays, rinses, inhalers or other treatments should I continue?
The outlook
For people whose polyps return quickly after surgery, being told that another operation is unlikely to solve the underlying problem can be disappointing. The arrival of biologic treatment changes that conversation. It offers a way of targeting the inflammation that drives polyp regrowth rather than repeatedly removing its consequences.
For patients who also have asthma and ABPA, the possibility is especially interesting: one targeted treatment may sometimes benefit the whole airway. It will not be the right answer for everybody, and it does not replace careful ABPA monitoring or antifungal treatment when needed. Nevertheless, it represents a significant and increasingly evidence-based addition to care.
Sources and further reading
- NICE: Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (2026).
- Bachert C, et al. Dupilumab in severe chronic rhinosinusitis with nasal polyps: SINUS-24 and SINUS-52. The Lancet (2019).
- Revised ISHAM-ABPA working group clinical practice guidelines. European Respiratory Journal (2024).
- Bourdin A, et al. Dupilumab efficacy in asthma and ABPA: LIBERTY ABPA AIRED. European Respiratory Journal conference abstract (2025).
- Dupixent UK Summary of Product Characteristics.
This information is intended to support, not replace, discussion with your medical team. Treatment eligibility and the balance of benefits and risks must be assessed individually.
Can We Predict Who Will Develop Aspergillosis? Genetics, Epigenetics and the Search for Individual Risk

Everyone inhales Aspergillus spores, usually every day, but only a small minority of people develop aspergillosis. Asthma, bronchiectasis, previous tuberculosis, lung cavities, transplantation and immune-suppressing treatment explain much of this difference—but not all of it.
Why does one person develop allergic bronchopulmonary aspergillosis (ABPA), another develop chronic pulmonary aspergillosis (CPA), and most people remain unaffected?
Researchers increasingly think that part of the answer lies in inherited differences affecting the airway lining, fungal recognition, immune-cell behaviour and inflammation. Epigenetics—the processes that alter how genes behave without changing the DNA sequence—may add another layer by connecting genetics with environment, exposure, inflammation and treatment.
Manchester has played an important part in this research. By combining patient DNA with studies of macrophages, airway cells, fungal load and gene editing, researchers have begun to show not merely which genetic variants are associated with aspergillosis, but how some of them might alter what happens when a fungal spore reaches the lung.
The central puzzle: exposure is common, disease is rare
Aspergillus spores are found in soil, compost, dust, decaying vegetation and indoor and outdoor air. Healthy lungs normally trap and remove inhaled spores before they can grow.
Several protective systems work together:
- mucus and moving airway cilia remove inhaled particles;
- airway epithelial cells form a protective barrier and detect fungal material;
- macrophages engulf spores that reach the air sacs;
- neutrophils attack spores that begin to germinate;
- antibodies, complement proteins and immune signals coordinate the response.
Aspergillosis becomes more likely when one or more of these defences is impaired—or when the immune response becomes excessive and allergic rather than protective.
Even so, people with apparently similar risk factors can have very different outcomes. Many people with severe asthma never develop ABPA. Many people with old tuberculosis cavities never develop CPA. Some transplant recipients develop invasive aspergillosis while others undergoing similar treatment do not.
This unexplained variation is what susceptibility genetics is trying to understand.
Genetic susceptibility is not genetic destiny
There is no single “aspergillosis gene”. Researchers instead distinguish between two broad forms of inherited risk.
Rare, high-impact variants
Rare harmful variants can cause recognised immune disorders such as chronic granulomatous disease and some hyper-IgE or combined immune-deficiency syndromes. These can substantially impair antifungal defence and occasionally lead to severe or invasive aspergillosis.
These disorders are important, but they do not explain most cases of ABPA or CPA. They are covered in more detail in our article Aspergillosis, immunity, and risk.
Common susceptibility variants
Common variants normally have much smaller effects. A variant might make the airway barrier slightly less effective, alter the removal of spores or make allergic inflammation more likely. On its own, the difference may cause no illness.
Risk may emerge only when several factors coincide:
- a susceptible airway or immune response;
- asthma or existing structural lung disease;
- corticosteroids or another immune-modifying treatment;
- repeated or heavy fungal exposure;
- ageing, infection, smoking or other acquired influences.
A susceptibility variant changes probability, not destiny. Having one does not mean that someone has aspergillosis or will develop it.
The Manchester genetics story
In 2014, University of Manchester researchers announced an ambitious project to investigate genetic susceptibility to CPA using next-generation exome sequencing.
An exome represents the protein-coding part of a person’s DNA. Although it accounts for only a small proportion of the complete genome, it contains many of the variants most likely to alter the structure or function of proteins.
The original project planned to examine approximately 160 patients from across the UK. Earlier research had concentrated on a limited number of immune genes. Exome sequencing allowed researchers to search much more widely and investigate pathways that might not previously have been connected with fungal disease.
Manchester’s wider patient and research collections have subsequently supported studies involving CPA, ABPA, fungal asthma and suitable control groups. The most informative discoveries have come from combining genetic findings with laboratory experiments.
This is important because a statistical association alone does not prove that a variant causes disease. Researchers need to show that the variant changes the behaviour of a relevant cell or biological pathway.
ZNF77: how the airway lining can encourage fungal growth
One of the clearest discoveries from Manchester’s exome work involved a variant called rs35699176 in ZNF77.
ZNF77 is a transcription factor, meaning that it helps regulate the activity of other genes. Researchers suspected that the variant might affect the bronchial epithelium—the layer of cells lining the airways.
Using CRISPR gene editing, the Manchester team recreated the variant in human bronchial epithelial cells. The altered cells:
- failed to form a normal, tightly joined epithelial layer;
- produced abnormal amounts of extracellular-matrix and adhesion proteins;
- allowed more Aspergillus fumigatus spores to attach;
- permitted earlier spore germination;
- supported greater subsequent fungal growth;
- produced altered inflammatory signals following fungal exposure.
Some extracellular-matrix proteins appeared to act rather like glue, making it easier for spores to adhere to the airway surface. Once attached, the spores germinated earlier and produced more extensive hyphal growth.
The researchers then looked for the same effect in patients. In the relatively small groups studied:
- people carrying the variant had approximately 15 times more A. fumigatus DNA in bronchoalveolar-lavage samples;
- among 45 people with ABPA, the variant was found in 9 of 32 with a positive sputum PCR but in none of the 13 with a negative PCR;
- carriers had approximately twice the fungal burden in sputum.
The major insight was that susceptibility does not have to involve conventional immune deficiency. An inherited difference in the physical and biochemical properties of the airway lining may make fungal colonisation easier.
However, the patient numbers were small and the association requires further validation. ZNF77 testing is not currently used routinely to predict fungal colonisation or ABPA.
EEA1: susceptibility can involve an overactive response
A separate Manchester study used exome sequencing in 96 people with ABPA and 167 asthmatic controls. Researchers identified variants in EEA1, a gene involved in the internal cellular compartments used to engulf and process material.
To test whether the association had a functional effect, the researchers studied macrophages obtained from people with ABPA.
Macrophages carrying the ABPA-associated EEA1 variants showed:
- increased uptake of A. fumigatus spores;
- increased acidification of the compartments containing them;
- an unusually active response to fungal material.
This finding was initially counterintuitive. The problem was not that the macrophages simply failed to respond. Instead, an exaggerated cellular response could contribute to the excessive inflammation characteristic of ABPA.
The study therefore provided another important lesson: genetic susceptibility can produce disease through too much inflammation as well as too little protection.
What has Manchester learned about CPA?
CPA usually develops in lungs already altered by previous tuberculosis, bronchiectasis, COPD, emphysema, sarcoidosis, non-tuberculous mycobacterial infection or other structural disease.
However, most people with these conditions do not develop CPA. Manchester researchers therefore compared immune responses and genetic variants in people with chronic cavitary pulmonary aspergillosis and control groups.
Their macrophage studies suggested a distinctive pattern:
- the initial response to fungal stimulation could be delayed;
- later production of inflammatory signals was greater;
- expression of several fungal-recognition receptors differed from healthy controls.
This supports a model in which early fungal clearance is not sufficiently effective, but is followed by a prolonged or excessive inflammatory response. That combination could allow Aspergillus to persist while also contributing to continuing lung damage.
Reported CPA associations have involved:
- IL1B, IL1RN and IL15, which participate in inflammatory signalling;
- TLR1 and CLEC7A/Dectin-1, which help recognise fungal material;
- VEGFA, involved in blood vessels and tissue repair;
- PLAT, involved in fibrinolysis and tissue remodelling;
- DENND1B, which participates in immune signalling.
These findings suggest relevant pathways, but they have not produced a clinically validated CPA screening panel.
Although the original Manchester project planned exome sequencing of approximately 160 people with CPA, a comprehensive final analysis of that entire cohort does not appear to have been published as a single definitive study. The available publications provide important mechanistic findings, but not a complete catalogue of validated CPA susceptibility variants.
What has been found more widely in ABPA?
Research from Manchester and elsewhere points towards several interacting processes in ABPA.
Type 2 allergic inflammation
IL-4 and IL-13 promote IgE production, eosinophilic inflammation, mucus secretion and other components of allergic immunity.
A Manchester-led association study investigated 195 variants across 22 genes. Associations involving IL13, IL4R and TLR3 remained significant after correction for multiple testing.
The findings support the idea that ABPA is not simply severe asthma combined with fungal exposure. Some people may inherit a tendency to mount an unusually strong or poorly regulated response to Aspergillus.
Airway clearance
CFTR is best known as the gene responsible for cystic fibrosis when a person inherits two disease-causing variants. Cystic fibrosis impairs mucus clearance and substantially increases the risk of ABPA.
Some people without cystic fibrosis carry one CFTR variant or have a milder CFTR-related disorder. Researchers are investigating whether reduced CFTR function contributes to mucus retention and fungal persistence in a subset of people with ABPA or bronchiectasis.
Fungal recognition
Associations have also been reported involving HLA variants, surfactant proteins and fungal-recognition pathways.
A 2023 study linked a heterozygous variant in CARD9 with ABPA. CARD9 transmits signals after immune cells recognise fungi. The finding is interesting, but it is not yet a clinically validated predictor.
PTX3 and invasive aspergillosis
The strongest progress towards clinically useful susceptibility testing has occurred in invasive aspergillosis, particularly after transplantation or intensive chemotherapy.
Pentraxin 3, or PTX3, binds to Aspergillus spores and helps neutrophils and other immune cells recognise and remove them.
Studies involving stem-cell and solid-organ transplant recipients have associated certain PTX3 variants with impaired antifungal activity and a higher risk of invasive aspergillosis.
In stem-cell transplantation, the donor’s genotype can matter because the donated cells produce the recipient’s new blood and immune cells.
A genetically guided prevention trial
The PTX3-targeted Antifungal Prophylaxis trial is testing whether genetic screening can help determine which people receiving intensive treatment for acute myeloid leukaemia should receive broad-spectrum antifungal prophylaxis.
Participants are tested for two PTX3 variants and placed into higher- or lower-risk groups. They are then assigned different prophylactic strategies involving posaconazole or fluconazole.
This is a significant step because the genetic result is not collected merely for future research: it is being used to stratify prevention within the trial.
There is currently no comparable genetic-screening trial for ABPA or CPA.
Summary of the principal candidate pathways
| Gene or pathway | Possible relevance | Current position |
|---|---|---|
| ZNF77 | Airway-barrier integrity, fungal adhesion and colonisation | Strong functional Manchester study; requires larger clinical validation |
| EEA1 | Macrophage uptake and processing of spores | ABPA association with supporting laboratory evidence |
| IL13 and IL4R | Type 2 allergic inflammation and IgE responses | Associated with ABPA, but not clinically predictive |
| HLA | Presentation and recognition of fungal proteins | Several reported ABPA associations; variable between populations |
| TLR and CLEC7A pathways | Recognition of fungal material | Candidate associations in ABPA, CPA and invasive disease |
| CFTR | Mucus clearance and airway defence | Important in cystic fibrosis; wider contribution remains under investigation |
| CARD9 | Signalling after fungal recognition | Rare deficiency causes major susceptibility; ABPA association is emerging |
| PTX3 | Labels spores for immune recognition and clearance | Strongest translational evidence in invasive aspergillosis |
What can epigenetics add?
The DNA sequence inherited from our parents is not the complete set of instructions used by every cell. Cells also regulate which genes are active, when they are activated and how strongly they are expressed.
Epigenetics describes mechanisms that influence gene activity without changing the underlying DNA sequence. These include:
- DNA methylation;
- chemical modification of histone proteins around which DNA is packaged;
- changes in chromatin accessibility;
- microRNAs and other molecules that regulate gene expression;
- longer-lasting reprogramming of innate immune cells, sometimes called trained immunity.
Some epigenetic patterns can change during life. They may be influenced by ageing, infection, smoking, air pollution, medication, inflammation and environmental exposure.
This makes epigenetics a plausible bridge between genes and environment. Two people could inherit similar genetic risks but develop different immune responses because their cells have experienced different exposures or illnesses.
Does DNA methylation cause susceptibility?
There is substantial evidence that DNA methylation is involved in asthma, allergy and immune development. Experimental work also shows that exposure to Aspergillus can alter gene expression and regulatory pathways in epithelial and immune cells.
However, direct human evidence that a particular methylation pattern causes susceptibility to ABPA or CPA remains very limited.
A methylation difference detected in someone with established aspergillosis could:
- have existed before the illness and contributed to susceptibility;
- have developed in response to fungal exposure or disease;
- reflect asthma, bronchiectasis or chronic inflammation;
- have been influenced by smoking, corticosteroids or other treatment;
- reflect a change in the types of cells present in the sample.
Researchers therefore need studies that collect samples before disease develops, or compare carefully matched groups, to distinguish cause from consequence.
Methylation is currently a promising research direction—not an established explanation for why an individual developed aspergillosis.
Patient genetics and fungal genetics are different
Manchester also maintains major resources relating to the genome of Aspergillus fumigatus itself.
The COFUN project aims to create approximately 10,000 fungal strains, each with a different gene removed. By observing what happens when individual genes are deleted, researchers can identify genes involved in:
- fungal growth and survival;
- pathogenicity and tissue damage;
- stress responses;
- azole and other antifungal resistance;
- potential new drug targets.
Manchester research has identified both conventional resistance mechanisms involving cyp51A and non-target mechanisms involving transporters, transcription factors, mitochondrial function and cellular signalling.
This is fungal genomics rather than human susceptibility genomics. Both are important, but they answer different questions: one examines why a patient may be vulnerable, while the other examines why a fungal strain may be particularly resistant or capable of causing disease.
Why is there still no clinical susceptibility test?
Several obstacles have slowed translation into patient care:
- ABPA, CPA and invasive aspergillosis have different mechanisms;
- many studies have included relatively few patients;
- variant frequencies differ between populations;
- underlying diseases and treatments are powerful confounding factors;
- some associations disappear when examined in independent cohorts;
- the effect of any one common variant is usually small;
- a statistical association does not necessarily demonstrate causation.
The Manchester ZNF77 and EEA1 studies are valuable because they went beyond association and demonstrated biological effects in relevant human cells. Even so, they require larger prospective clinical validation before testing can guide care.
Could several markers be combined?
A useful prediction system is unlikely to depend on one gene. It may combine:
- multiple genetic variants in a polygenic risk score;
- immune-cell function and inflammatory biomarkers;
- gene-expression and epigenetic patterns;
- CT findings and the extent of lung damage;
- asthma, bronchiectasis, COPD or previous tuberculosis;
- corticosteroids and other immune-modifying treatments;
- fungal sensitisation, antibodies, culture and PCR;
- environmental exposure.
This combined approach is sometimes called multi-omics or precision medicine. Rather than searching for one faulty gene, researchers examine how inherited variation, gene regulation, immune cells, lung structure, fungal biology and exposure interact.
Is testing useful for patients now?
There is currently no clinically validated genetic, polygenic or methylation test that can reliably predict ABPA or CPA.
Specialist genetic or immunological investigation may nevertheless be appropriate when aspergillosis:
- occurs unusually early in life;
- is recurrent, invasive or affects unusual sites;
- occurs without the expected lung or treatment-related risk factors;
- is accompanied by recurrent bacterial, viral or other fungal infections;
- occurs alongside features suggesting an inherited immune disorder.
Commercial sequencing can also identify a variant of uncertain significance. This means that a DNA difference has been found but there is insufficient evidence to determine whether it affects health. Such a result is not a diagnosis and requires specialist interpretation.
Routine genetic testing of healthy relatives of people with ABPA or CPA is not currently recommended solely because of the family connection.
What this means for patients
The Manchester research has helped replace a simple idea—“some patients have weak immunity”—with a more sophisticated picture.
Susceptibility may involve:
- an airway surface that allows spores to adhere and germinate;
- immune recognition that starts too slowly;
- a later response that becomes excessive or damaging;
- mucus that is difficult to clear;
- several small inherited differences acting alongside lung damage and exposure.
Genetics probably contributes to the striking differences between people exposed to the same fungus. Epigenetic regulation may add another layer by allowing inflammation, treatment and environment to influence how genes behave.
But current evidence does not show that most people with aspergillosis carry a single faulty gene. Nor can a genetic or methylation test yet tell most patients precisely why they became ill or predict what will happen next.
The immediate value of this research is a better understanding of disease mechanisms. Its longer-term promise is more practical: identifying people who need closer monitoring, selecting preventive treatment for those at greatest risk and matching treatment to the biological pathway driving disease.
For now, symptoms, clinical history, lung structure, immune status, imaging and established fungal tests remain much more important than susceptibility genetics in diagnosing and managing aspergillosis.
Selected research and further reading
- University of Manchester: the original CPA exome-sequencing project.
- Gago S et al. Lung colonisation by Aspergillus fumigatus is controlled by ZNF77.
- Overton NLD et al. EEA1 variants, ABPA and macrophage phagocytosis.
- Overton NLD et al. Genetic susceptibility to ABPA in asthma.
- Smith NL et al. IL-1 and IL-15 pathways in chronic cavitary pulmonary aspergillosis.
- Smith NL et al. Macrophage receptor expression and genetic associations in chronic cavitary pulmonary aspergillosis.
- PTX3-targeted antifungal prophylaxis trial.
- Manchester Fungal Infection Group.
- Aspergillosis, immunity, and risk.
Last reviewed: August 2026
Air Conditioning, Mould and Aspergillosis

Air conditioning can make hot weather more comfortable and may help reduce indoor humidity. However, any system that becomes damp, dirty or poorly maintained can provide conditions in which mould and bacteria grow.
This is particularly important for people with aspergillosis, severe asthma, bronchiectasis or other respiratory conditions. Air conditioning does not inevitably expose people to Aspergillus—the condition and maintenance of the equipment are what matter.
How can mould develop in an air-conditioning system?
Air conditioners cool warm air. As the air cools, water condenses on the cooling coils and should drain safely away. Problems can develop when:
- condensate collects in a blocked, damaged or poorly draining tray;
- filters and internal surfaces accumulate dust and remain damp;
- the unit or surrounding building has a water leak;
- the equipment is left unused while damp and dirty;
- maintenance and filter replacement are neglected.
Damp dust and debris can support fungal growth. Air moving through contaminated equipment may then carry fungal particles, fragments and odours into the occupied room. UK indoor-air guidance recommends regular cleaning and filter replacement to maintain ventilation performance and reduce microbial growth and bioaerosols.
Can air conditioning help prevent mould?
Yes. Correctly sized and properly maintained air conditioning can remove moisture from indoor air. This may make mould growth less likely, particularly during warm, humid weather.
A conventional air conditioner normally uses a refrigerant circuit, similar to a refrigerator or heat pump. Warm indoor air passes over a cold evaporator coil, where water vapour condenses. The collected water is then:
- carried away through a condensate drain;
- collected in a tank that must be emptied; or
- in some portable units, evaporated again and expelled outside with the hot air through the exhaust hose.
During very humid conditions, a self-evaporating portable unit may still collect more water than it can expel, so its internal tank may need emptying.
An air conditioner must also release the heat it has removed. Fixed split systems use an outdoor condenser, while portable air conditioners usually discharge hot air through a hose fitted to a window or external vent. A unit with no refrigerant compressor and no way to release heat outside is unlikely to be a true room air conditioner.
A unit that is too large may cool a room quickly without removing enough moisture, while a poorly maintained or blocked unit may leak water or allow condensation to accumulate.
Air conditioners and evaporative air coolers are different
Some portable devices are marketed as “air conditioners,” “mini air conditioners” or “personal air conditioners” but are actually evaporative air coolers. These pass air across wet paper, pads, filters or wicks.
Evaporation can make the outgoing air feel cooler, but these devices add water to the indoor air rather than removing it. They work less effectively in humid conditions and may be unsuitable in a home that is already damp or poorly ventilated.
Their water tanks and continually wet internal surfaces also require careful cleaning and drying according to the manufacturer’s instructions. If neglected, they may support the growth of mould or bacteria.
Before buying or using a portable cooling unit, check whether it:
- uses a refrigerant and compressor;
- has an exhaust hose or outdoor condenser through which heat is released;
- removes condensate into a drain or collection tank; or
- relies on a water reservoir and wet pad to cool the air by evaporation.
This distinction is important for anyone trying to reduce indoor humidity or mould exposure.
Warning signs that need attention
Stop using the unit and arrange an inspection if you notice:
- a persistent musty or mouldy smell when it is running;
- visible mould around the vents or inside an accessible cover;
- water dripping from the unit or collecting beneath it;
- a persistently wet filter or condensate tray;
- a noticeable worsening of respiratory symptoms when the unit is operating.
These signs do not prove that Aspergillus is present, but they indicate that the system needs investigation.
Using air conditioning safely at home
- Follow the manufacturer’s servicing and filter-cleaning schedule. Different systems require different intervals.
- Make sure condensate drains freely and investigate any water leakage promptly.
- Replace disposable filters rather than washing them unless the manufacturer specifically describes the filter as washable.
- Keep the area around outdoor air intakes free from compost, decaying vegetation and other obvious sources of dust and mould.
- Do not fit a very dense filter unless the system is designed for it. Restricting airflow can reduce performance and cause additional condensation.
- Remember that many domestic split air-conditioning units recirculate indoor air and do not provide fresh-air ventilation. Continue to ventilate the room appropriately.
A portable HEPA air cleaner may reduce some airborne particles, but it will not correct a contaminated air-conditioning unit, blocked drain or damp building.
Should someone with aspergillosis clean the unit?
People with aspergillosis should not dismantle or clean visibly contaminated equipment themselves. Opening the unit, brushing a filter or using compressed air could release accumulated dust and fungal material.
Ask someone without a respiratory condition to undertake straightforward routine filter maintenance, following the manufacturer’s instructions. Visible mould, a musty smell, internal contamination or drainage problems should be assessed by a competent air-conditioning engineer or ventilation specialist.
Tell the engineer that somebody in the property has aspergillosis or another serious respiratory condition. Ask how contaminated material will be contained and whether the person should leave the room or property while the work is undertaken.
Air conditioning in cars
Vehicle systems can also develop musty odours when the cabin filter is dirty or moisture remains around the evaporator. Have the cabin filter and drainage system checked during routine servicing. A persistent smell should be investigated rather than covered with an air freshener or deodorising spray.
At work, in hotels and while travelling
You may not be responsible for maintaining equipment at work or in rented accommodation, hotels and holiday properties. If a unit smells musty, leaks water or appears visibly dirty:
- switch it off if it is safe and practical to do so;
- ask for another room or working area;
- report the problem to the employer, landlord or accommodation manager;
- do not open or clean an unfamiliar unit yourself.
A musty smell alone cannot identify the organism involved, and respiratory symptoms can have many causes. Seek medical advice if symptoms become severe or do not settle after leaving the affected environment.
Further information
- UK Government: Indoor Air Quality Report
- US Environmental Protection Agency: mould and HVAC systems
- How can I remove mould from my home safely?
- Aspergillosis Housing Hub



When Coughing Becomes Socially Difficult
One reader described an experience that is rarely captured by scans or lung-function tests.
They noticed that meeting and talking with other people naturally changed their breathing. Deeper breaths, speaking and emotional excitement seemed to mobilise congestion, followed by a coughing episode. The physical need to cough then created anxiety about coughing in front of others.
This illustrates how several real processes can overlap:
Research has not established exactly how each part of this sequence operates in aspergillosis, so we should not pretend that one explanation fits everyone. The cough and mucus are nevertheless physical, while the social anxiety is also real. Each can intensify the other.
What may help?
The goal is not to suppress a cough that is needed to clear mucus. It is to make the episode safer, more manageable and less socially limiting.